| Q95359387 | Q95359387 |
| Q92931968 | "Living a normal life": a qualitative study of patients' views of medication withdrawal in rheumatoid arthritis |
| Q40770857 | (18)F-FDG and (18)F-NaF PET/CT demonstrate coupling of inflammation and accelerated bone turnover in rheumatoid arthritis |
| Q35233222 | (5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway |
| Q88757204 | 18F- FDG PET/CT joint assessment of early therapeutic response in rheumatoid arthritis patients treated with rituximab |
| Q60054124 | 2-D speckle-tracking assessment of left and right ventricular function in rheumatoid arthritis patients with and without disease activity |
| Q34085682 | 25(OH) vitamin D serum values and rheumatoid arthritis disease activity (DA S28 ESR) |
| Q91938966 | A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis |
| Q58052135 | A Functional Ser413/Ser413 PAI-2 Polymorphism Is Associated With Susceptibility and Damage Index Score in Systemic Lupus Erythematosus |
| Q53215562 | A Method for Delineation of Bone Surfaces in Photoacoustic Computed Tomography of the Finger. |
| Q93083086 | A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis |
| Q46930972 | A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis |
| Q34533371 | A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy |
| Q47755963 | A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis |
| Q92051649 | A Study of the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis |
| Q34788695 | A broad analysis of IL1 polymorphism and rheumatoid arthritis. |
| Q55689959 | A case of Caplan syndrome in a recently diagnosed patient with silicosis: A case report. |
| Q35141960 | A close association of body cell mass loss with disease activity and disability in Chinese patients with rheumatoid arthritis |
| Q35326449 | A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis |
| Q52643879 | A critical epitope in CD147 facilitates memory CD4+ T-cell hyper-activation in rheumatoid arthritis. |
| Q50882786 | A distinct human CD4+ T cell subset that secretes CXCL13 in rheumatoid synovium. |
| Q34486243 | A double-blind, randomized controlled trial to compare the effect of biannual peripheral magnetic resonance imaging, radiography and standard of care disease progression monitoring on pharmacotherapeutic escalation in rheumatoid and undifferentiated |
| Q36994587 | A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis |
| Q36028278 | A functional variant in FCRL3 is associated with higher Fc receptor-like 3 expression on T cell subsets and rheumatoid arthritis disease activity. |
| Q36477515 | A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis |
| Q36924733 | A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity |
| Q50624588 | A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. |
| Q39325262 | A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control |
| Q55252682 | A multi-modal MRI study of the central response to inflammation in rheumatoid arthritis. |
| Q64088699 | A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Huangqi Guizhi Wuwutang granule in patients with rheumatoid arthritis |
| Q36473075 | A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission |
| Q38198117 | A nationwide cross-sectional overview of patients with rheumatoid arthritis followed in outpatient specialty clinics in Finland. |
| Q95302182 | A new laboratory surrogate (Monocyte Chemotactic Protein-1) for Disease Activity Score28: a favourable indicator for remission in rheumatoid arthritis |
| Q92892516 | A novel bioavailable hydrogenated curcuminoids formulation (CuroWhite™) improves symptoms and diagnostic indicators in rheumatoid arthritis patients - A randomized, double blind and placebo controlled study |
| Q52372777 | A novel gene and pathway-level subtyping analysis scheme to understand biological mechanisms in complex disease: a case study in rheumatoid arthritis. |
| Q40625154 | A patient-initiated DMARD self-monitoring service for people with rheumatoid or psoriatic arthritis on methotrexate: a randomised controlled trial |
| Q34346378 | A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis |
| Q52562279 | A phase I/II randomized, controlled, clinical trial for assessment of the efficacy and safety of β-D-mannuronic acid in rheumatoid arthritis patients. |
| Q46483294 | A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors |
| Q37546519 | A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis |
| Q35557430 | A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine |
| Q37500085 | A potential role of myeloid DAP12-associating lectin (MDL)-1 in the regulation of inflammation in rheumatoid arthritis patients |
| Q36084979 | A profile of immune response to herpesvirus is associated with radiographic joint damage in rheumatoid arthritis. |
| Q37245184 | A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue |
| Q40372208 | A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate |
| Q36775820 | A randomised, controlled study of outcome and cost effectiveness for RA patients attending nurse-led rheumatology clinics: study protocol of an ongoing nationwide multi-centre study |
| Q41449525 | A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis |
| Q33675468 | A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial |
| Q89684666 | A randomized controlled trial to reduce sedentary time in rheumatoid arthritis: protocol and rationale of the Take a STAND for Health study |
| Q92898397 | A randomized study comparing regular care with a nurse-led clinic based on tight disease activity control and person-centred care in patients with rheumatoid arthritis with moderate/high disease activity: A 6-month evaluation |
| Q34361354 | A randomized trial of three psychosocial treatments for the symptoms of rheumatoid arthritis |
| Q54761549 | A randomized, controlled trial of efficacy and safety of Anbainuo, a bio-similar etanercept, for moderate to severe rheumatoid arthritis inadequately responding to methotrexate. |
| Q87526876 | A randomized, double-blind, and placebo-controlled multicenter clinical trial of a novel cytotoxic T-lymphocyte antigen-4 fusion protein, Leining, in Chinese active rheumatoid arthritis patients with an inadequate response to methotrexate |
| Q43101622 | A randomized, double-blind, sham-controlled study of static electric field therapy by high voltage alternating current for active rheumatoid arthritis |
| Q33923332 | A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass. |
| Q87785825 | A reduced 12-joint ultrasound examination predicts lack of X-ray progression better than clinical remission criteria in patients with rheumatoid arthritis |
| Q36907647 | A regulatory effect of IL-21 on T follicular helper-like cell and B cell in rheumatoid arthritis |
| Q38153099 | A retrospective chart review of the use of rituximab for the treatment of rheumatoid arthritis in Australian rheumatology practice |
| Q38236514 | A review of disease activity measures for psoriatic arthritis: what is the best approach? |
| Q53100234 | A simplified and validated ultrasound scoring system to evaluate synovitis of bilateral wrists and hands in patients with rheumatoid arthritis. |
| Q36900659 | A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis |
| Q58484343 | A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis |
| Q31105054 | A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes. |
| Q57349848 | A two‐year follow‐up of work capacity in early rheumatoid arthritis: a study of multidisciplinary team care with emphasis on vocational support |
| Q35139150 | A variant in the osteoprotegerin gene is associated with coronary atherosclerosis in patients with rheumatoid arthritis: results from a candidate gene study |
| Q34552239 | A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats |
| Q35907768 | A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release |
| Q62633597 | ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate |
| Q54357187 | AC13, a C-terminal fragment of apolipoprotein A-I, is a candidate biomarker for microscopic polyangiitis. |
| Q45419013 | Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis |
| Q34752154 | Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry. |
| Q36193944 | Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. |
| Q48044952 | Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study |
| Q34449851 | Abatacept: the evidence for its place in the treatment of rheumatoid arthritis |
| Q34233328 | Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics |
| Q35840749 | Aberrant splicing of the hRasGRP4 transcript and decreased levels of this signaling protein in the peripheral blood mononuclear cells in a subset of patients with rheumatoid arthritis |
| Q58234722 | Ability of Interleukin-33- and Immune Complex-Triggered Activation of Human Mast Cells to Down-Regulate Monocyte-Mediated Immune Responses |
| Q52587395 | Absence of Fibrosis and Inflammation by Cardiac Magnetic Resonance Imaging in Rheumatoid Arthritis Patients with Low to Moderate Disease Activity. |
| Q44654704 | Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience |
| Q58102049 | Acceptable quality of life and low disease activity achievable among transition phase patients with rheumatic disease |
| Q42121483 | Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone |
| Q35543487 | Acquired permanent dislocation of the patella in a patient with rheumatoid genu valgum |
| Q54316357 | Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy. |
| Q91891005 | Activation of the Peroxisome Proliferator-Activated Receptor γ Coactivator 1β/NFATc1 Pathway in Circulating Osteoclast Precursors Associated With Bone Destruction in Rheumatoid Arthritis |
| Q39908952 | Active Foot Synovitis in Patients With Rheumatoid Arthritis: Unstable Remission Status, Radiographic Progression, and Worse Functional Outcomes in Patients With Foot Synovitis in Apparent Remission |
| Q31159540 | Active synovitis in the presence of osteitis predicts residual synovitis in patients with rheumatoid arthritis with a clinical response to treatment |
| Q90457501 | Activity of rheumatoid arthritis correlates with oral inflammatory burden |
| Q40134581 | Acupuncture for symptom management of rheumatoid arthritis: a pilot study |
| Q24817087 | Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score |
| Q54339705 | Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. |
| Q35953319 | Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial |
| Q35637990 | Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study |
| Q36708319 | Adalimumab for rheumatoid arthritis |
| Q48025048 | Adalimumab markedly improves enthesitis in patients with psoriatic arthritis: Evaluation with a magnetic resonance imaging scoring system |
| Q33830219 | Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study |
| Q37210194 | Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study |
| Q34118958 | Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study |
| Q47553449 | Adaptation and Validation of the Foot Function Index-Revised Short Form into Polish. |
| Q50573619 | Adaptation to an autoimmune disorder: Does mental flexibility impact illness-related self-regulation? |
| Q49945512 | Adaptation to inflammatory rheumatic disease: Do illness representations predict patients' physical functioning over time? A complex relationship. |
| Q46157064 | Adding low dose tacrolimus in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies |
| Q41937791 | Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial |
| Q50198473 | Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study. |
| Q36907691 | Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort |
| Q50914337 | Adherence to uric acid treatment guidelines in a rheumatology clinic. |
| Q45012451 | Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis |
| Q33950766 | Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. |
| Q37380362 | Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis |
| Q51067097 | Adipose Tissue Macrophages in Rheumatoid Arthritis: Prevalence, Disease-Related Indicators, and Associations With Cardiometabolic Risk Factors. |
| Q34287829 | Adipose depots, not disease-related factors, account for skeletal muscle insulin sensitivity in established and treated rheumatoid arthritis |
| Q46048883 | Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial |
| Q88342966 | Advanced Power Doppler Technique Increases Synovial Vascularity Detection in Patients with Rheumatoid Arthritis |
| Q35907814 | Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease |
| Q42374261 | Advanced myocardial tissue characterisation by a multi-component CMR protocol in patients with rheumatoid arthritis |
| Q36288599 | Advances in the treatment of inflammatory arthritis |
| Q35131783 | Advantages of a combined rheumatoid arthritis magnetic resonance imaging score (RAMRIS) for hand and feet: does the RAMRIS of the hand alone underestimate disease activity and progression? |
| Q42378594 | Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA). |
| Q42918622 | Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA). |
| Q48355389 | Aerobic capacity over 16 years in patients with rheumatoid arthritis: Relationship to disease activity and risk factors for cardiovascular disease |
| Q33765844 | Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. |
| Q87050900 | Age impacts on the independent relationships of leptin with cardiometabolic risk and surrogate markers of enhanced early atherogenesis in black and white patients with rheumatoid arthritis: a cross-sectional study |
| Q39243813 | Age- and Sex-Dependent Changes of Intra-articular Cortical and Trabecular Bone Structure and the Effects of Rheumatoid Arthritis |
| Q40309503 | Albuminuria in Rheumatoid Arthritis: Associations with RA Characteristics and Subclinical Atherosclerosis |
| Q36923243 | Alteration of matrix metalloproteinase-3 O-glycan structure as a biomarker for disease activity of rheumatoid arthritis. |
| Q36182763 | Alterations in skin microvascular function in patients with rheumatoid arthritis and ankylosing spondylitis |
| Q48138068 | Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy. |
| Q35047250 | American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials |
| Q36984426 | Amino-terminal fragment of the prohormone brain-type natriuretic peptide in rheumatoid arthritis |
| Q50553806 | Amino-terminal pro-brain natriuretic peptide as a prognostic marker in patients with rheumatoid arthritis |
| Q28294375 | An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis |
| Q33511764 | An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. |
| Q36778521 | An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression |
| Q39110166 | An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy |
| Q46066669 | An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents |
| Q37658783 | Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study. |
| Q24241707 | Anakinra for rheumatoid arthritis |
| Q24243387 | Anakinra for rheumatoid arthritis |
| Q33620448 | Analysis of correlation and causes for discrepancy between quantitative and semi-quantitative Doppler scores in synovitis in rheumatoid arthritis |
| Q36681791 | Analysis of distribution and severity of inflammation in patients with osteoarthitis compared to rheumatoid arthritis by ICG-enhanced fluorescence optical imaging and musculoskeletal ultrasound: a pilot study |
| Q44518151 | Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis |
| Q33579417 | Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis |
| Q83283951 | Anemia in rheumatoid arthritis: high prevalence of iron-deficiency anemia in Indian patients |
| Q35067205 | Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis |
| Q38855074 | Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis |
| Q58134440 | Anti-Citrullinated Cyclic Peptide Antibody and Functional Disability Are Associated With Poor Sleep Quality in Rheumatoid Arthritis |
| Q35674628 | Anti-Cyclic Citrullinated Peptide Antibodies and Severity of Interstitial Lung Disease in Women with Rheumatoid Arthritis |
| Q24816803 | Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis |
| Q39704305 | Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis. |
| Q44790776 | Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modification |
| Q36151574 | Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy |
| Q53195970 | Anti-TNFα agents curb platelet activation in patients with rheumatoid arthritis. |
| Q34348277 | Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study. |
| Q83189340 | Anti-agalactosyl IgG antibody in ankylosing spondylitis and psoriatic arthritis |
| Q38602504 | Anti-carbamylated protein antibodies presence in early arthritis with a poorer clinical and radiological outcome: data from the French ESPOIR cohort |
| Q31167745 | Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients. |
| Q61799672 | Anti-citrullinated protein antibodies are associated with osteopenia but not with pain at diagnosis of rheumatoid arthritis: data from the BARFOT cohort |
| Q51155261 | Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. |
| Q36633289 | Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. |
| Q36776959 | Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. |
| Q39526831 | Antibodies against M. Bovis 65 KDa Heat Shock Protein and Its P180-188 Epitope in Sera of Patients with Juvenile Idiopathic Arthritis |
| Q90355984 | Antibodies against citrullinated peptides are associated with clinical and radiological outcomes in patients with early rheumatoid arthritis: a prospective longitudinal inception cohort study |
| Q35637080 | Antibodies against human 60 kDa heat shock protein are not associated with cardiovascular disease in patients with rheumatoid arthritis |
| Q43195995 | Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis |
| Q51070244 | Antibodies to Cyclic Citrullinated Peptides in Patients With Juvenile Idiopathic Arthritis and Patients With Rheumatoid Arthritis: Shared Expression of the Inherently Autoreactive 9G4 Idiotype. |
| Q41248107 | Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study. |
| Q36641506 | Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study |
| Q21195370 | Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy |
| Q39669606 | Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs |
| Q44484495 | Anti–citrullinated protein antibody positivity correlates with cartilage damage and proteoglycan levels in patients with rheumatoid arthritis in the hand joints |
| Q40747812 | Anxiety and depression in rheumatoid arthritis: an epidemiologic survey and investigation of clinical correlates in Iranian population |
| Q48446936 | Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life |
| Q36554649 | Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis |
| Q30426777 | Application of high frequency color Doppler ultrasound in the monitoring of rheumatoid arthritis treatment |
| Q34476049 | Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists |
| Q45984342 | Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. |
| Q89099586 | Are Illness Perceptions Associated With Disease Activity or Psychological Well-Being in Rheumatoid Arthritis? A Study With the Evidence of Confirmatory Factor Analysis |
| Q51673816 | Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis? |
| Q43673759 | Are personal characteristics associated with exercise participation in patients with rheumatoid arthritis? A cross-sectional explorative survey |
| Q55100474 | Area of Residence and Socioeconomic Factors Reduce Access to Biologics for Rheumatoid Arthritis Patients in Romania. |
| Q47676328 | Arterial Inflammation Detected With 18 F-Fluorodeoxyglucose-Positron Emission Tomography in Rheumatoid Arthritis |
| Q51610024 | Arterial stiffness in a muscular artery in women with longstanding rheumatoid arthritis compared with healthy controls and patients with traditional cardiovascular risk factors. |
| Q87035377 | Arterial stiffness is associated with left ventricular dysfunction in patients with rheumatoid arthritis |
| Q57037211 | Arthroscopic synovectomy of the knee joint for rheumatoid arthritis |
| Q82288460 | Articular damage in adults with juvenile idiopathic arthritis |
| Q38521375 | Ascites and other incidental findings revealing undiagnosed systemic rheumatoid arthritis |
| Q36486374 | Aspects of early arthritis. Traditional DMARD therapy: is it sufficient? |
| Q35605542 | Aspects of early arthritis. What determines the evolution of early undifferentiated arthritis and rheumatoid arthritis? An update from the Norfolk Arthritis Register |
| Q47679436 | Assessing joint destruction in the knees of patients with rheumatoid arthritis by using a semi-automated software for magnetic resonance imaging: therapeutic effect of methotrexate plus etanercept compared with methotrexate monotherapy |
| Q51275859 | Assessing rheumatologists and radiologists agreement rate regarding the diagnosis of focal bone erosions and osteopenic changes using hand X-rays radiography in patients with rheumatoid arthritis. |
| Q53742456 | Assessment of Corneal and Tear Film Parameters in Rheumatoid Arthritis Patients Using Anterior Segment Spectral Domain Optical Coherence Tomography. |
| Q49650969 | Assessment of Vitamin D in Rheumatoid Arthritis and Its Correlation with Disease Activity |
| Q37737644 | Assessment of anti-CarP antibodies, disease activity and quality of life in rheumatoid arthritis patients on conventional and biological disease-modifying antirheumatic drugs |
| Q35129324 | Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan. |
| Q34346209 | Assessment of myocardial abnormalities in rheumatoid arthritis using a comprehensive cardiac magnetic resonance approach: a pilot study |
| Q37523537 | Assessment of the -174G/C (rs1800795) and -572G/C (rs1800796) Interleukin 6 Gene Polymorphisms in Egyptian Patients with Rheumatoid Arthritis |
| Q98564424 | Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN |
| Q53654897 | Assessment of the effectiveness of golimumab 50-mg and 100-mg regimens in patients with rheumatoid arthritis in daily practice. |
| Q34394122 | Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of t |
| Q39210570 | Assistive devices: usage in patients with rheumatoid arthritis |
| Q50737007 | Associated factors for falls and fear of falling in Japanese patients with rheumatoid arthritis. |
| Q56988177 | Association Among Rheumatoid Arthritis, Oral Hygiene, and Periodontitis |
| Q48250371 | Association Between Atrial, Ventricular and Vascular Morphofunctional Alterations in Rheumatoid Arthritis. |
| Q37169541 | Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis. |
| Q48271582 | Association between CD266 polymorphism and soluble levels in rheumatoid arthritis: Relationship with clinical activity. |
| Q64245654 | Association between Negatively Charged Low-Density Lipoprotein L5 and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients |
| Q59791522 | Association between autophagy and inflammation in patients with rheumatoid arthritis receiving biologic therapy |
| Q46674650 | Association between mean platelet volume and severity of rheumatoid arthritis |
| Q89699804 | Association between periodontitis and anti-citrullinated protein antibodies in rheumatoid arthritis patients: a cross-sectional study |
| Q37471597 | Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds |
| Q38600510 | Association between serum vitamin D levels and neuropathic pain in rheumatoid arthritis patients: A cross-sectional study. |
| Q61446181 | Association between severity of periodontitis and clinical activity in rheumatoid arthritis patients: a case-control study |
| Q36382714 | Association between socioeconomic status, learned helplessness, and disease outcome in patients with inflammatory polyarthritis |
| Q89601177 | Association between vitamin D and fatigue in patients with rheumatoid arthritis: a cross-sectional study |
| Q60947575 | Association of Angiogenic and Inflammatory Markers with Power Doppler Ultrasound Vascularity Grade and DAS28-CRP in Early Rheumatoid Arthritis: A Comparative Analysis |
| Q41425374 | Association of Anti-Porphyromonas gingivalis Antibody Titers With Nonsmoking Status in Early Rheumatoid Arthritis: Results From the Prospective French Cohort of Patients With Early Rheumatoid Arthritis |
| Q36403294 | Association of Elevations of Specific T Cell and Monocyte Subpopulations in Rheumatoid Arthritis With Subclinical Coronary Artery Atherosclerosis |
| Q42053368 | Association of Improvement in Pain With Therapeutic Response as Determined by Individual Improvement Criteria in Patients With Rheumatoid Arthritis |
| Q48330739 | Association of MICA-129 polymorphism and circulating soluble MICA level with rheumatoid arthritis in a south Indian Tamil population |
| Q92832855 | Association of MTMR3 rs12537 at miR-181a binding site with rheumatoid arthritis and systemic lupus erythematosus risk in Egyptian patients |
| Q41550162 | Association of Nocturnal Hypertension With Disease Activity in Rheumatoid Arthritis |
| Q46840442 | Association of PTPN22 1858C→T polymorphism, HLA-DRB1 shared epitope and autoantibodies with rheumatoid arthritis. |
| Q36640598 | Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial |
| Q37662605 | Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomi |
| Q24800622 | Association of a specific haplotype across the genes MMP1 and MMP3 with radiographic joint destruction in rheumatoid arthritis |
| Q99564907 | Association of age with the non-achievement of clinical and functional remission in rheumatoid arthritis |
| Q46951195 | Association of anti-CCP positivity with serum ferritin and DAS-28. |
| Q37163594 | Association of body fat with C-reactive protein in rheumatoid arthritis. |
| Q43538492 | Association of brain functional magnetic resonance activity with response to tumor necrosis factor inhibition in rheumatoid arthritis |
| Q36528874 | Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis |
| Q33717110 | Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease |
| Q52983676 | Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. |
| Q37179297 | Association of epicardial adipose tissue with cardiometabolic risk and metabolic syndrome in patients with rheumatoid arthritis |
| Q37445635 | Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease |
| Q57796538 | Association of galectin-3 with markers of myocardial function, atherosclerosis and vascular fibrosis in patients with rheumatoid arthritis |
| Q58771663 | Association of high titers of anti-carbamylated protein antibodies with decreased bone mineral density in early arthritis patients |
| Q36732088 | Association of interleukin-6 and interleukin-10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status. |
| Q36939442 | Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate |
| Q44621683 | Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate |
| Q38320019 | Association of mannose-binding lectin gene (MBL2) polymorphisms with rheumatoid arthritis in an Indian cohort of case-control samples |
| Q53703233 | Association of nocturnal blood pressure patterns with inflammation and central and peripheral estimates of vascular health in rheumatoid arthritis. |
| Q47885394 | Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. |
| Q48291335 | Association of oxidative stress with clinical characteristics in patients with rheumatoid arthritis |
| Q35541874 | Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis. |
| Q34063456 | Association of physical function and physical activity in women with rheumatoid arthritis |
| Q37000109 | Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis |
| Q35614010 | Association of single nucleotide polymorphism at position -308 of the tumor necrosis factor-alpha gene with ankylosing spondylitis and rheumatoid arthritis. |
| Q35788276 | Association of socioeconomic status with treatment delays, disease activity, joint damage, and disability in rheumatoid arthritis |
| Q51108293 | Association of the 5A/6A promoter polymorphism of the MMP-3 gene with the radiographic progression of rheumatoid arthritis. |
| Q44838586 | Association of the HLA-G 14-bp insertion/deletion polymorphism with juvenile idiopathic arthritis and rheumatoid arthritis |
| Q60297012 | Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients |
| Q57306851 | Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis |
| Q51757080 | Association of tri-nucleotide (CAG and GGC) repeat polymorphism of androgen receptor gene in Taiwanese women with refractory or remission rheumatoid arthritis. |
| Q39272864 | Association of tumour necrosis factor-alpha -308 G/A promoter polymorphism with susceptibility and disease profile of rheumatoid arthritis. |
| Q36291358 | Association of vitamin D with cardiometabolic risk factors in rheumatoid arthritis |
| Q47782073 | Associations Between Five Important Domains of Health and the Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross-Sectional Study of 977 Patients |
| Q89208039 | Associations between D3R expression in synovial mast cells and disease activity and oxidant status in patients with rheumatoid arthritis |
| Q43476748 | Associations between HLA-DRB1, RANK, RANKL, OPG, and IL-17 genotypes and disease severity phenotypes in Japanese patients with early rheumatoid arthritis |
| Q46068058 | Associations between methotrexate treatment and methylenetetrahydrofolate reductase gene polymorphisms with incident fractures in Japanese female rheumatoid arthritis patients |
| Q39825022 | Associations of Circulating Cytokines and Chemokines With Cancer Mortality in Men With Rheumatoid Arthritis |
| Q35025293 | Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry |
| Q41921823 | Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications |
| Q33596873 | Associations of smoking and alcohol consumption with disease activity and functional status in rheumatoid arthritis |
| Q35110147 | Asymptomatic atherosclerosis in egyptian rheumatoid arthritis patients and its relation to disease activity |
| Q50978964 | Asymptomatic celiac sprue in juvenile rheumatic diseases children. |
| Q46071397 | Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial |
| Q34897630 | Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study |
| Q34153114 | Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness |
| Q34776189 | Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis |
| Q37550010 | Autoantibodies and other serological markers in rheumatoid arthritis: predictors of disease activity? |
| Q48184228 | Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus |
| Q39933222 | Autoantibodies to human citrullinated fibrinogen and their subfamilies to the α36-50Cit and β60-74Cit fibrin peptides similarly predict radiographic damages: a prospective study in the French ESPOIR cohort of very early arthritides. |
| Q51075481 | Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. |
| Q24800888 | Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment |
| Q36869886 | Autonomic Dysfunction Precedes Development of Rheumatoid Arthritis: A Prospective Cohort Study |
| Q46269700 | Autonomic impairment in rheumatoid arthritis. |
| Q24187687 | Ayurveda interventions for rheumatoid arthritis |
| Q55176650 | Azilsartan as "Add-On" Treatment with Methotrexate Improves the Disease Activity of Rheumatoid Arthritis. |
| Q58797436 | Azilsartan improves the effects of etanercept in patients with active rheumatoid arthritis: a pilot study |
| Q33923459 | B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy |
| Q45047971 | Bacterial infections of the rheumatoid foot |
| Q94327588 | Baricitinib for rheumatoid arthritis |
| Q37604501 | Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study |
| Q37696609 | Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment |
| Q43867998 | Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity |
| Q37748066 | Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis |
| Q35637343 | Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register |
| Q53826993 | Baseline serum level of matrix metalloproteinase-3 as a biomarker of progressive joint damage in rheumatoid arthritis patients. |
| Q45246408 | Basic treatment of early rheumatoid arthritis. Abstaining from rheumatological care and preferring alternative medicine increase the risk of undertreatment |
| Q87204069 | Behçet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab |
| Q30397751 | Being an outpatient with rheumatoid arthritis--a focus group study on patients' self-efficacy and experiences from participation in a short course and one of three different outpatient settings |
| Q37347655 | Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity |
| Q60935709 | Benefits of wrist splinting in patients with rheumatoid arthritis |
| Q39169435 | Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis. |
| Q44814337 | Bi(o)communications among peripheral blood fractions: a focus on NK and NKT cell biology in rheumatoid arthritis |
| Q56975651 | Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis |
| Q37177593 | Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register |
| Q24240731 | Biologics for rheumatoid arthritis: an overview of Cochrane reviews |
| Q24240891 | Biologics for rheumatoid arthritis: an overview of Cochrane reviews |
| Q92416998 | Biomarkers associated with cardiovascular disease in patients with early rheumatoid arthritis |
| Q26776432 | Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity? |
| Q36218552 | Biomarkers of rheumatoid arthritis-associated interstitial lung disease |
| Q34621522 | Blockade of TNF-α rapidly inhibits pain responses in the central nervous system |
| Q37621002 | Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker. |
| Q50980453 | Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. |
| Q34576441 | Blood monocyte chemotactic protein-1 (MCP-1) and adapted disease activity Score28-MCP-1: favorable indicators for rheumatoid arthritis activity |
| Q34003845 | Blood monocyte subsets and selected cardiovascular risk markers in rheumatoid arthritis of short duration in relation to disease activity |
| Q42863433 | Blood serum levels of amino-terminal pro-C-type natriuretic peptide in patients with rheumatoid arthritis |
| Q89498878 | Body Mass Index and Clinical Response to Tocilizumab in Patients With Rheumatoid Arthritis |
| Q39761544 | Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis |
| Q54340309 | Bone erosion is associated with reduction of circulating endothelial progenitor cells and endothelial dysfunction in rheumatoid arthritis. |
| Q34897514 | Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs |
| Q35620308 | Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis |
| Q84049863 | Bone mineral density and frequency of osteoporosis among Vietnamese women with early rheumatoid arthritis |
| Q34056836 | Bone mineral density by digital X-ray radiogrammetry is strongly decreased and associated with joint destruction in long-standing rheumatoid arthritis: a cross-sectional study |
| Q36143682 | Bone mineral density changes during treatment of rheumatoid arthritis with disease-modifying-anti-rheumatic drugs |
| Q35440451 | Bone mineral density changes in patients with recent-onset rheumatoid arthritis |
| Q86145893 | Bone mineral density of postmenopausal women with rheumatoid arthritis depends on disease duration regardless of treatment |
| Q54369171 | Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis. |
| Q42500618 | Bosentan, an endothelin receptor antagonist, ameliorates collagen-induced arthritis: the role of TNF-α in the induction of endothelin system genes |
| Q40055726 | Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis. |
| Q39824928 | Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab |
| Q58204609 | Brief Report: Leucine-Rich α2-Glycoprotein as a Potential Biomarker for Joint Inflammation During Anti-Interleukin-6 Biologic Therapy in Rheumatoid Arthritis |
| Q38858594 | Brief Report: Management of Chronic Post-Chikungunya Rheumatic Disease: The Martinican Experience |
| Q51028545 | Brief Report: Miscarriages in Female Rheumatoid Arthritis Patients: Associations With Serologic Findings, Disease Activity, and Antirheumatic Drug Treatment. |
| Q42538647 | Brief Report: Proatherogenic Cytokine Microenvironment in the Aortic Adventitia of Patients With Rheumatoid Arthritis |
| Q42285413 | Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria |
| Q40481610 | Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis. |
| Q45917390 | Brief Report: to squeeze or not to squeeze, that is the question! Optimizing the disease activity score in 28 joints by adding the squeeze test of metatarsophalangeal joints in early rheumatoid arthritis. |
| Q39254767 | Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener's). |
| Q37333972 | Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion |
| Q34098412 | Brief report: rheumatoid arthritis response criteria and patient-reported improvement in arthritis activity: is an American College of Rheumatology twenty percent response meaningful to patients? |
| Q45925746 | CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. |
| Q54170357 | CCR2 Expression in Neutrophils Plays a Critical Role in Their Migration Into the Joints in Rheumatoid Arthritis. |
| Q82332974 | CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis |
| Q28728734 | CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis |
| Q35659545 | CD8+ T Cells Specific to Apoptosis-Associated Antigens Predict the Response to Tumor Necrosis Factor Inhibitor Therapy in Rheumatoid Arthritis |
| Q58329736 | Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin‐like growth factor |
| Q33456382 | Calibration of the PROMIS physical function item bank in Dutch patients with rheumatoid arthritis |
| Q52807047 | Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. |
| Q53212565 | Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab. |
| Q37584844 | Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis |
| Q47253535 | Calprotectin (S100A8/A9) should preferably be measured in EDTA-plasma; results from a longitudinal study of patients with rheumatoid arthritis |
| Q37080199 | Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. |
| Q60044823 | Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study |
| Q42678356 | Can Cyclosporine-A Associated to Methotrexate Maintain Remission Induced by Anti-TNF Agents in Rheumatoid Arthritis Patients? (Cynar Pilot Study) |
| Q39164961 | Can Rheumatologists Predict Eventual Need for Orthopaedic Intervention in Patients with Rheumatoid Arthritis? Results of a Systematic Review and Analysis of Two UK Inception Cohorts |
| Q37203499 | Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis? |
| Q48891747 | Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up |
| Q50230068 | Can mean platelet volume and red blood cell distribution width show disease activity in rheumatoid arthritis? |
| Q64929171 | Cardiorespiratory fitness in patients with rheumatoid arthritis is associated with the patient global assessment but not with objective measurements of disease activity. |
| Q51773790 | Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis. |
| Q28390163 | Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis |
| Q35617716 | Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study |
| Q47859328 | Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project |
| Q55405320 | Cardiovascular system changes in rheumatoid arthritis patients with continued low disease activity. |
| Q37390580 | Carotid Artery Atherosclerosis in Patients with Active Rheumatoid Arthritis: Predictors of Plaque Occurrence and Progression Over 24 Weeks. |
| Q59794786 | Carotid artery volumetric measures associate with clinical ten-year cardiovascular (CV) risk scores and individual traditional CV risk factors in rheumatoid arthritis; a carotid-MRI feasibility study |
| Q35777047 | Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis |
| Q47827555 | Cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and its correlation with sonographic knee cartilage thickness and disease activity. |
| Q40813488 | Cause-Specific Mortality in Male US Veterans With Rheumatoid Arthritis |
| Q90215839 | Cell adhesion molecules and plasminogen activator inhibitor type-1 (PAI-1) in patients with rheumatoid arthritis: influence of metabolic syndrome |
| Q55000881 | Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis. |
| Q51211966 | Challenges of cardiovascular risk assessment in the routine rheumatology outpatient setting: an observational study of 110 rheumatoid arthritis patients. |
| Q36320021 | Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis |
| Q36796741 | Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK). |
| Q33390403 | Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study |
| Q55305483 | Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases. |
| Q44174557 | Changes in body composition after 2 years with rheumatoid arthritis |
| Q42634337 | Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis |
| Q34395306 | Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. |
| Q35954510 | Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis |
| Q48883146 | Changes in peripheral blood B cell subsets at diagnosis and after treatment with disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: correlation with clinical and laboratory parameters |
| Q33552038 | Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy |
| Q36204182 | Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti-tumour necrosis factor treatment. |
| Q51051361 | Changes in regulatory B cells and their relationship with rheumatoid arthritis disease activity. |
| Q42123635 | Changes in sirtuin 2 and sirtuin 3 mRNA expressions in rheumatoid arthritis |
| Q45964494 | Changes in sociodemographic characteristics at baseline in two Swedish cohorts of patients with early rheumatoid arthritis diagnosed 1996-98 and 2006-09. |
| Q35638554 | Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment |
| Q90450556 | Characteristics of Appendicular Tissue Components in Patients with Rheumatoid Arthritis |
| Q90603171 | Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis |
| Q50965039 | Characterization of effector memory CD8+ T cells in the synovial fluid of rheumatoid arthritis. |
| Q35804294 | Chemokine receptors expression on peripheral CD4-lymphocytes in rheumatoid arthritis: Coexpression of CCR7 and CD95 is associated with disease activity. |
| Q51131123 | Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. |
| Q50591145 | Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012. |
| Q36790369 | Cigarette smoking associates with body weight and muscle mass of patients with rheumatoid arthritis: a cross-sectional, observational study. |
| Q59806580 | Circulating Semaphorin 4D as a Marker for Predicting Radiographic Progression in Patients with Rheumatoid Arthritis |
| Q51016390 | Circulating cell free DNA: a marker to predict the therapeutic response for biological DMARDs in rheumatoid arthritis. |
| Q36013933 | Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis |
| Q45913731 | Circulating plasma levels of cathepsin S and L are not associated with disease severity in patients with rheumatoid arthritis. |
| Q36929564 | Circulating secretory IgA antibodies against cyclic citrullinated peptides in early rheumatoid arthritis associate with inflammatory activity and smoking |
| Q33923272 | Circulating surfactant protein -D is low and correlates negatively with systemic inflammation in early, untreated rheumatoid arthritis |
| Q92301896 | Citrullinated Inhibitor of DNA Binding 1 Is a Novel Autoantigen in Rheumatoid Arthritis |
| Q45987541 | Citrullination of epithelial neutrophil-activating peptide 78/CXCL5 results in conversion from a non-monocyte-recruiting chemokine to a monocyte-recruiting chemokine. |
| Q37691111 | Classical cardiovascular disease risk factors associate with vascular function and morphology in rheumatoid arthritis: a six-year prospective study. |
| Q37143744 | Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. |
| Q35924965 | Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity |
| Q34897423 | Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register |
| Q74163617 | Clinical and functional status in 88 rheumatoid arthritis patients followed for 15 years or more by office-based (n = 41) or hospital-based (n = 47) physicians |
| Q85857547 | Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis |
| Q48915370 | Clinical and psychosocial factors associated with depression and anxiety in Singaporean patients with rheumatoid arthritis |
| Q58703890 | Clinical and radiologic analysis of on-demand use of etanercept for disease flares in patients with rheumatoid arthritis for 2 years: The RESUME study: A case-control study |
| Q51733091 | Clinical and radiological features of rheumatoid arthritis in British black Africans. |
| Q50250607 | Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the M |
| Q92843762 | Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis |
| Q37690878 | Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year |
| Q37267600 | Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study |
| Q81091752 | Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis |
| Q26995307 | Clinical outcomes in psoriatic arthritis: A systematic literature review |
| Q36648604 | Clinical pathways as instruments for risk and cost management in hospitals - a discussion paper |
| Q35636558 | Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology |
| Q35249636 | Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study |
| Q35954497 | Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis |
| Q46893265 | Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry |
| Q81640635 | Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis |
| Q35953220 | Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis |
| Q36832755 | Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis |
| Q36550842 | Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s |
| Q41976428 | Clinical, laboratory, and ultrasound assessment of the knee in juvenile rheumatoid arthritis |
| Q35223223 | Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study |
| Q28652859 | Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials |
| Q34576969 | Clinically important changes in short form 36 health survey scales for use in rheumatoid arthritis clinical trials: the impact of low responsiveness |
| Q36513993 | Co-morbidity in patients with early rheumatoid arthritis - inflammation matters |
| Q46642268 | Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression |
| Q37296406 | Combined infliximab and methotrexate treatment improves the depressive state in rheumatoid arthritis patients more effectively than methotrexate alone |
| Q54747658 | Combined measurement of multiple acute phase reactants to predict relapse of rheumatoid arthritis. |
| Q82736530 | Combined use of propagation velocity and intraventricular dispersion of E wave velocity for the evaluation of diastolic functions in patients with rheumatoid arthritis |
| Q55068670 | Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. |
| Q51801169 | Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors. |
| Q38815347 | Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points |
| Q52932746 | Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features. |
| Q59329016 | Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries |
| Q39885959 | Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study |
| Q37689953 | Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients |
| Q48907082 | Comparative quality of life in patients with depression and rheumatoid arthritis |
| Q48494568 | Comparative responsiveness of the EuroQol-5D and Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry |
| Q35056149 | Comparing Five Year Out-Come in Two Cohorts of Patients with Early Rheumatoid Arthritis - A BARFOT Study |
| Q47367147 | Comparison between different disease activity scores in rheumatoid arthritis: an Egyptian multicenter study. |
| Q35760044 | Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values |
| Q85913598 | Comparison of OMERACT-RAMRIS scores and computer-aided dynamic magnetic resonance imaging findings of hand and wrist as a measure of activity in rheumatoid arthritis |
| Q82037538 | Comparison of composite disease activity indices for rheumatoid arthritis |
| Q36171802 | Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort |
| Q39804264 | Comparison of elderly- and young-onset rheumatoid arthritis in an Asian cohort |
| Q50121805 | Comparison of foot pain and foot care among rheumatoid arthritis patients taking and not taking anti-TNFα therapy: an epidemiological study. |
| Q81658198 | Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial |
| Q42666679 | Comparison of patient satisfaction with two different etanercept delivery systems. A randomised controlled study in patients with rheumatoid arthritis |
| Q39109424 | Comparison of peripheral quantitative computed tomography forearm bone density versus DXA in rheumatoid arthritis patients and controls. |
| Q35901757 | Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumatoid Arthritis |
| Q40900014 | Comparison of the DAS28-CRP and DAS28-ESR in patients with rheumatoid arthritis |
| Q37703462 | Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis |
| Q50534516 | Comparison of the disease activity score using the erythrocyte sedimentation rate and C-reactive protein levels in Koreans with rheumatoid arthritis. |
| Q53179392 | Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. |
| Q24630541 | Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study |
| Q33849849 | Comparison of two assays to determine anti-citrullinated peptide antibodies in rheumatoid arthritis in relation to other chronic inflammatory rheumatic diseases: assaying anti-modified citrullinated vimentin antibodies adds value to second-generatio |
| Q36220832 | Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study. |
| Q35557840 | Comparisons of 7- to 78-joint ultrasonography scores: all different joint combinations show equal response to adalimumab treatment in patients with rheumatoid arthritis |
| Q45966283 | Complement receptor type 1 (CR1, CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patients. |
| Q36343783 | Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis |
| Q47149296 | Comprehensive analysis of long non-coding RNA and mRNA expression profiles in rheumatoid arthritis |
| Q33668001 | Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies |
| Q36374666 | Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis? |
| Q56985494 | Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis |
| Q57741148 | Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis |
| Q40606444 | Concordance of Patient-Reported Joint Symptoms, Physician-Examined Arthritic Signs, and Ultrasound-Detected Synovitis in Rheumatoid Arthritis |
| Q43421019 | Concurrent psychiatric disorders are associated with significantly poorer quality of life in patients with rheumatoid arthritis |
| Q50108380 | Cone-beam computed tomography, a new low-dose three-dimensional imaging technique for assessment of bone erosions in rheumatoid arthritis: reliability assessment and comparison with conventional radiography - a BARFOT study |
| Q35768186 | Constitutive STAT3 Phosphorylation in Circulating CD4+ T Lymphocytes Associates with Disease Activity and Treatment Response in Recent-Onset Rheumatoid Arthritis |
| Q34768971 | Constitutively altered frequencies of circulating follicullar helper T cell counterparts and their subsets in rheumatoid arthritis |
| Q44358193 | Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. |
| Q97873762 | Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial |
| Q35869031 | Contribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumor necrosis factor-alpha gene promoter |
| Q51030572 | Contribution of subjective Disease Activity Score 28 (DAS28) components to the response to treatment of rheumatoid arthritis. |
| Q53662356 | Contribution of the subjective components of the disease activity score to the response to biologic treatment in rheumatoid arthritis. |
| Q55079883 | Control of articular synovitis for bone and cartilage regeneration in rheumatoid arthritis. |
| Q57819586 | Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long‐term infliximab therapy |
| Q37246482 | Coronary Artery Calcification Is Related to Inflammation in Rheumatoid Arthritis: A Long-Term Follow-Up Study |
| Q40556371 | Coronary Artery Calcification and Rheumatoid Arthritis: Lack of Relationship to Risk Alleles for Coronary Artery Disease in the General Population |
| Q37206907 | Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis |
| Q58491706 | Correlación y concordancia de la autoclinimetría en artritis reumatoide: revisión sistemática de la literatura y metanálisis |
| Q52004662 | Correlates of patients' global assessment of arthritis impact. A 2-year study of 216 patients with RA. |
| Q90415381 | Correlates of sedentary behaviour and light physical activity in people living with rheumatoid arthritis: protocol for a longitudinal study |
| Q40054338 | Correlation analyses revealed global microRNA-mRNA expression associations in human peripheral blood mononuclear cells. |
| Q43426073 | Correlation between DAS-28 and neopterin as a biochemical marker of immune system activation in early rheumatoid arthritis |
| Q39066165 | Correlation between rapid-3, DAS28, CDAI and SDAI as a measure of disease activity in a cohort of Colombian patients with rheumatoid arthritis. |
| Q36633196 | Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study S |
| Q36830958 | Correlation of Paraoxonase Status with Disease Activity Score and Systemic Inflammation in Rheumatoid Arthritic Patients |
| Q35907845 | Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study |
| Q41219509 | Correlation of rheumatoid arthritis activity indexes (Disease Activity Score 28 measured with ESR and CRP, Simplified Disease Activity Index and Clinical Disease Activity Index) and agreement of disease activity states with various cut-off points in |
| Q24798428 | Correlation of the score for subjective pain with physical disability, clinical and radiographic scores in recent onset rheumatoid arthritis |
| Q30251996 | Correlations between fatigue and disease duration, disease activity, and pain in patients with rheumatoid arthritis: a systematic review. |
| Q38013786 | Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model |
| Q94452927 | Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis |
| Q44960639 | Cost-effectiveness of a one-year coaching program for healthy physical activity in early rheumatoid arthritis |
| Q35809549 | Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. |
| Q92147073 | Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis |
| Q48278236 | Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry. |
| Q92551580 | Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry |
| Q35605415 | Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. |
| Q34427742 | Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible |
| Q45972867 | Cross-cultural adaptation and validation of the Thai version of the Rheumatoid Arthritis Disease Activity Index (RADAI). |
| Q37201814 | Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis |
| Q38179268 | Cumulative disease activity predicts incidental hearing impairment in patients with rheumatoid arthritis (RA). |
| Q34112840 | Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents |
| Q36125286 | Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis |
| Q51640866 | Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival. |
| Q59335170 | DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs |
| Q24812386 | DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment |
| Q45734541 | DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt. |
| Q99627753 | DAS28-CRP Cutoffs for High Disease Activity and Remission Are Lower Than DAS28-ESR in Rheumatoid Arthritis |
| Q24812591 | DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis |
| Q39154858 | DNA methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis. |
| Q36004805 | DREAMTools: a Python package for scoring collaborative challenges. |
| Q31061167 | Data-driven desirability function to measure patients' disease progression in a longitudinal study |
| Q35637402 | Declines in number of tender and swollen joints in patients with rheumatoid arthritis seen in standard care in 1985 versus 2001: possible considerations for revision of inclusion criteria for clinical trials |
| Q40501745 | Decrease in bone mineral density during three months after diagnosis of early rheumatoid arthritis measured by digital X-ray radiogrammetry predicts radiographic joint damage after one year. |
| Q58543113 | Decreased Expression of Sphingosine-1-Phosphate Receptor 1 in the Blood Leukocyte of Rheumatoid Arthritis Patients |
| Q38831392 | Decreased Serotonin Levels and Serotonin-Mediated Osteoblastic Inhibitory Signaling in Patients With Ankylosing Spondylitis. |
| Q34473650 | Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis |
| Q64945673 | Decreased regulatory T-cell frequency and interleukin-35 levels in patients with rheumatoid arthritis. |
| Q35617658 | Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. |
| Q39539735 | Defining criteria for rheumatoid arthritis patient-derived disease activity score that correspond to Disease Activity Score 28 and Clinical Disease Activity Index based disease states and response criteria. |
| Q36246062 | Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID) |
| Q44513624 | Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score. |
| Q37130290 | Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population |
| Q64055293 | Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab |
| Q35070822 | Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis |
| Q48406726 | Depression history, stress, and pain in rheumatoid arthritis patients |
| Q47725236 | Depressive and anxiety symptoms and social support are independently associated with disease-specific quality of life in Colombian patients with rheumatoid arthritis |
| Q46796548 | Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors |
| Q35840753 | Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis |
| Q24816844 | Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study |
| Q56570654 | Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Imact of esidual Inflammation Detected via Imaging Tchniques, rug Levels and Patient Characteristics on the Outcome of Dose Taperng of Adalimumab in linical Remissi |
| Q37105384 | Determinants of brachial-ankle pulse wave velocity in Chinese patients with rheumatoid arthritis |
| Q38439965 | Determinants of methotrexate adherence in rheumatoid arthritis patients |
| Q36898455 | Determination of the diagnostic values of asymmetric dimethylarginine as an indicator for evaluation of the endothelial dysfunction in patients with rheumatoid arthritis |
| Q48079611 | Determining Pathways to Improvements in Fatigue in Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis |
| Q35961312 | Determining the Lowest Optimally Effective Methotrexate Dose for Individual RA Patients Using Their Dose Response Relation in a Tight Control Treatment Approach |
| Q36087222 | Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients. |
| Q96219375 | Developing Smartphone-Based Objective Assessments of Physical Function in Rheumatoid Arthritis Patients: The PARADE Study |
| Q90329265 | Developing new therapeutic approaches for rheumatoid arthritis: the continuing challenges of clinical assessments |
| Q64931203 | Development and application of a questionnaire to assess patient beliefs in rheumatoid arthritis and axial spondyloarthritis. |
| Q37329497 | Development and evaluation of a crosswalk between the SF-36 physical functioning scale and Health Assessment Questionnaire disability index in rheumatoid arthritis. |
| Q37745045 | Development and psychometric properties of a joint protection self-efficacy scale |
| Q47627654 | Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire |
| Q44525783 | Development and validation of a new disease activity index as a numerical sum of four variables in patients with early arthritis |
| Q60304759 | Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis |
| Q36179586 | Development and validation of a risk score for serious infection in patients with rheumatoid arthritis |
| Q34667793 | Development of a multi-biomarker disease activity test for rheumatoid arthritis |
| Q35759939 | Development of comprehensive disease assessment in systemic vasculitis |
| Q37207010 | Developments in the clinical understanding of rheumatoid arthritis |
| Q41200262 | Dextromethorphan Exhibits Anti-inflammatory and Immunomodulatory Effects in a Murine Model of Collagen-Induced Arthritis and in Human Rheumatoid Arthritis |
| Q38165235 | Diagnosing and treating psoriatic arthritis: an update |
| Q92615743 | Diagnosing coeliac disease: Out with the old and in with the new? |
| Q92895044 | Diagnosing fibromyalgia in rheumatoid arthritis: The importance of assessing disease activity |
| Q49009690 | Diagnosis and referral of rheumatoid arthritis by primary care physician: results of a pilot study on the city of Pisa, Italy |
| Q37453967 | Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis. |
| Q35760128 | Diagnostic quality and scoring of synovitis, tenosynovitis and erosions in low-field MRI of patients with rheumatoid arthritis: a comparison with conventional MRI |
| Q37740969 | Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis - the TryCort study. |
| Q35808002 | Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis |
| Q33923250 | Diagnostic value of anti-cyclic citrullinated peptides and association with HLA-DRB1 shared epitope alleles in African rheumatoid arthritis patients |
| Q90457374 | Diagnostic value of salivary CRP and IL-6 in patients undergoing anti-TNF-alpha therapy for rheumatic disease |
| Q90419436 | Diastolic dysfunction in rheumatoid arthritis patients with low disease activity |
| Q38858884 | Dietary Intake of Polyunsaturated Fatty Acids and Pain in spite of Inflammatory Control among Methotrexate Treated Early Rheumatoid Arthritis Patients |
| Q93089741 | Diets high in n-3 fatty acids are associated with lower arterial stiffness in patients with rheumatoid arthritis: a latent profile analysis |
| Q48640400 | Differences between questionnaire- and interview-based measures of activities of daily living (ADL) ability and their association with observed ADL ability in women with rheumatoid arthritis, knee osteoarthritis, and fibromyalgia. |
| Q36083920 | Different Measures, Different Outcomes? A Systematic Review of Performance-Based versus Self-Reported Measures of Health Literacy and Numeracy |
| Q37130442 | Different methods of balancing covariates leading to different effect estimates in the presence of effect modification |
| Q39874212 | Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial |
| Q44980231 | Different wording of the Patient Global Visual Analogue Scale (PG-VAS) affects rheumatoid arthritis patients' scoring and the overall Disease Activity Score (DAS28): a cross-sectional study |
| Q41482717 | Differential Association of Psychosocial Comorbidities With Subclinical Atherosclerosis in Rheumatoid Arthritis |
| Q37023870 | Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis |
| Q33593925 | Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration |
| Q61800845 | Differential expression and regulation of the non-integrin 37/67-kDa laminin receptor on peripheral blood leukocytes of healthy individuals and patients with rheumatoid arthritis |
| Q40005303 | Differential gene expression of peripheral blood mononuclear cells from rheumatoid arthritis patients may discriminate immunogenetic, pathogenic and treatment features |
| Q36907478 | Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker |
| Q39128814 | Dilemmas of participation in everyday life in early rheumatoid arthritis: a qualitative interview study (The Swedish TIRA Project). |
| Q39215790 | Diminished soluble levels of growth arrest specific protein 6 and tyrosine kinase receptor Axl in patients with rheumatoid arthritis |
| Q46083591 | Disabilities of importance for patients to improve--using a patient preference tool in rheumatoid arthritis |
| Q51916190 | Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms. |
| Q43752980 | Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab |
| Q35048301 | Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study |
| Q37690027 | Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study |
| Q84564364 | Discontinuation of etanercept in patients with rheumatoid arthritis who were in clinical remission |
| Q54518906 | Discordance between clinical and imaging criteria: assessment by magnetic resonance imaging of the foot of patients with rheumatoid arthritis. |
| Q48139626 | Discordance of global estimates by patients and their physicians in usual care of many rheumatic diseases: association with 5 scores on a Multidimensional Health Assessment Questionnaire (MDHAQ) that are not found on the Health Assessment Questionna |
| Q50554784 | Discrepancies in categorizing rheumatoid arthritis patients by DAS-28(ESR) and DAS-28(CRP): can they be reduced? |
| Q47689292 | Discrepancy between subjective and objective measures of cognitive impairment in patients with rheumatoid arthritis. |
| Q35954667 | Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis pat |
| Q42677290 | Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER |
| Q54984291 | Disease Characteristics and Change in Arthritis Activity according to Treatment in Hepatitis B Surface Antigen-positive Rheumatoid Arthritis Patients: a Retrospective Chart Review Study. |
| Q34376211 | Disease Progression and Treatment Responses in a Prospective DMARD-naive Seropositive Early Rheumatoid Arthritis Cohort: Does Gender Matter? |
| Q48960736 | Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score |
| Q47318571 | Disease activity, handgrip strengths, and hand dexterity in patients with rheumatoid arthritis. |
| Q39310097 | Disease activity, resilience and health-related quality of life in Chinese patients with rheumatoid arthritis: a multi-center, cross-sectional study |
| Q41521795 | Disease duration of rheumatoid arthritis is a predictor of vascular stiffness: a cross-sectional study in patients without known cardiovascular comorbidities: A STROBE-compliant article |
| Q40133444 | Disease patterns of rheumatology outpatients seen in a tertiary hospital serving a multi-ethnic, urban Asian population in Singapore |
| Q38698132 | Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature |
| Q44550260 | Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice |
| Q33831409 | Disease-modifying anti-rheumatic drug use according to the 'sawtooth' treatment strategy improves the functional outcome in rheumatoid arthritis: results of a long-term follow-up study with review of the literature |
| Q37374953 | Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database |
| Q64059626 | Distal interphalangeal joint extensor tendon enthesopathy in patients with nail psoriasis |
| Q33563703 | Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic Diseases |
| Q35138666 | Distinct effects of anti-tumor necrosis factor combined therapy on TH1/TH2 balance in rheumatoid arthritis patients |
| Q39336915 | Distinct trajectories of disease activity over the first year in early rheumatoid arthritis patients following a treat-to-target strategy |
| Q35859109 | Distressed personality is associated with lower psychological well-being and life satisfaction, but not disability or disease activity in rheumatoid arthritis patients |
| Q85230267 | Distribution of interleukin-10 family cytokines in serum and synovial fluid of patients with inflammatory arthritis reveals different contribution to systemic and joint inflammation |
| Q84644585 | Disturbed Th17/Treg balance in patients with rheumatoid arthritis |
| Q38039360 | Do dynamic strengthening and aerobic capacity exercises reduce pain and improve functional outcomes and strength in people with established rheumatoid arthritis? |
| Q35431243 | Do patients with juvenile idiopathic arthritis in clinical remission have evidence of persistent inflammation on 3T magnetic resonance imaging? |
| Q33766248 | Does digital X-ray radiogrammetry have a role in identifying patients at increased risk for joint destruction in early rheumatoid arthritis? |
| Q40597614 | Does disease activity add to functional disability in estimation of utility for rheumatoid arthritis patients on biologic treatment? |
| Q44718935 | Does modern treatment of early rheumatoid arthritis reduce the need for intra-articular glucocorticoids? |
| Q91775337 | Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Do |
| Q33870043 | Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. |
| Q35637979 | Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. |
| Q24198056 | Down titration and discontinuation strategies of tumor necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity |
| Q24193435 | Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity |
| Q47974635 | Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases |
| Q41693369 | Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register |
| Q37593506 | Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis |
| Q44616013 | Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases |
| Q33795738 | Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement |
| Q49370571 | Drug survival and the associated predictors in South Korean patients with rheumatoid arthritis receiving tacrolimus |
| Q54967304 | Drug-free remission: the goal of the future in management of patients with rheumatoid arthritis. |
| Q34081925 | Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). |
| Q37292191 | Drugs Used in the Treatment of Rheumatoid Arthritis: Relationship between Current Use and Cardiovascular Risk Factors |
| Q35834171 | Dual X-Ray Absorptiometry Whole Body Composition of Bone Tissue in Rheumatoid Arthritis - a Cross-Sectional Study |
| Q41016595 | Dual X-ray Absorptiometry Whole Body Composition of Adipose Tissue in Rheumatoid Arthritis |
| Q53309363 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Pharmacokinetic Modeling: Initial Experience in Patients With Early Arthritis. |
| Q58704524 | Dysregulated ICOS proinflammatory and suppressive regulatory T cells in patients with rheumatoid arthritis |
| Q37521891 | ECG non-specific ST-T and QTc abnormalities in patients with systemic lupus erythematosus compared with rheumatoid arthritis |
| Q26778262 | EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide |
| Q34894822 | Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis |
| Q92771523 | Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study |
| Q92737266 | Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials |
| Q54417889 | Early rheumatoid arthritis 6 years after diagnosis is still associated with high direct costs and increasing loss of productivity: the Swedish TIRA project. |
| Q34409903 | Early vascular alterations in SLE and RA patients--a step towards understanding the associated cardiovascular risk |
| Q53656576 | Echocardiographic evaluation of diastolic dysfunction in rheumatoid arthritis - a case-control study. |
| Q37144969 | Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States. |
| Q53760790 | Editorial: The Enduring Value of Reporting Randomized Controlled Clinical Trials in Arthritis & Rheumatology: 2016 and Beyond. |
| Q43524523 | Editorial: inflammation, disease-modifying antirheumatic drugs, lipids, and cardiovascular risk in rheumatoid arthritis |
| Q82263506 | Effect of Atorvastatin on Inflammation and Modification of Vascular Risk Factors in Rheumatoid Arthritis |
| Q40959053 | Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis |
| Q92115742 | Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial |
| Q60955224 | Effect of Methotrexate in the Treatment of Distal Interphalangeal Joint Extensor Tendon Enthesopathy in Patients with Nail Psoriasis |
| Q36421939 | Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial |
| Q87034577 | Effect of Xinfeng capsule in the treatment of active rheumatoid arthritis: a randomized controlled trial |
| Q44844209 | Effect of age at menopause on disease presentation in early rheumatoid arthritis: results from the Canadian Early Arthritis Cohort |
| Q51260814 | Effect of anti-tumor necrosis factor alpha treatment of rheumatoid arthritis and chronic kidney disease. |
| Q46931844 | Effect of chronic periodontitis on oxidative status in patients with rheumatoid arthritis. |
| Q40061605 | Effect of disease-modifying antirheumatic drug therapy on immune response to trivalent influenza vaccine in rheumatoid arthritis |
| Q60930175 | Effect of high-intensity interval training on muscle remodeling in rheumatoid arthritis compared to prediabetes |
| Q35742831 | Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial |
| Q55049410 | Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. |
| Q45900492 | Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. |
| Q87586879 | Effect of methotrexate use and erythrocyte methotrexate polyglutamate on glycosylated hemoglobin in rheumatoid arthritis |
| Q60912117 | Effect of patient education on medication adherence of patients with rheumatoid arthritis: a randomized controlled trial |
| Q37115728 | Effect of periodontal treatment on the clinical parameters of patients with rheumatoid arthritis: study protocol of the randomized, controlled ESPERA trial |
| Q48192721 | Effect of spa therapy with saline balneotherapy on oxidant/antioxidant status in patients with rheumatoid arthritis: a single-blind randomized controlled trial |
| Q42544241 | Effective rheumatoid arthritis treatment requires comprehensive management strategies |
| Q40735887 | Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry |
| Q37356217 | Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis |
| Q34012929 | Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). |
| Q55315590 | Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. |
| Q39603215 | Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study. |
| Q33566374 | Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions |
| Q50098260 | Effectiveness of an overall progressive resistance strength program for improving the functional capacity of patients with rheumatoid arthritis: a randomized controlled trial. |
| Q41647134 | Effectiveness of arthroscopic elbow synovectomy in rheumatoid arthritis patients: Long-term follow-up of clinical and functional outcomes |
| Q33881065 | Effector T helper cell populations are elevated in the bone marrow of rheumatoid arthritis patients and correlate with disease severity |
| Q90111774 | Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis |
| Q22299388 | Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis |
| Q44067316 | Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis |
| Q41127155 | Effects of Concomitant Methotrexate on Large Joint Replacement in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors: A Multicenter Retrospective Cohort Study in Japan |
| Q39680232 | Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis. |
| Q42683590 | Effects of Whole-Body Cryotherapy in Comparison with Other Physical Modalities Used with Kinesitherapy in Rheumatoid Arthritis. |
| Q43761211 | Effects of a group-based exercise and educational program on physical performance and disease self-management in rheumatoid arthritis: a randomized controlled study |
| Q30841797 | Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry. |
| Q35521765 | Effects of cigarette smoking on early arthritis: a cross-sectional study-data from the Argentine Consortium for Early Arthritis (CONAART). |
| Q43446274 | Effects of different local cryotherapies on systemic levels of TNF-α, IL-6, and clinical parameters in active rheumatoid arthritis |
| Q54322103 | Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group stud |
| Q54493171 | Effects of glucosamine administration on patients with rheumatoid arthritis. |
| Q82257624 | Effects of intravenous iron saccharate on improving severe anemia in rheumatoid arthritis patients |
| Q82906930 | Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity |
| Q35760806 | Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis |
| Q36725347 | Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. |
| Q34533379 | Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate |
| Q41468717 | Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial. |
| Q37267285 | Efficacy and Safety of Rituximab in Biologic-Naive Patients with Rheumatoid Arthritis vs Anti-Tnf Therapy Failure |
| Q38375767 | Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis. |
| Q37143729 | Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate |
| Q47617640 | Efficacy and safety of Xinfeng capsule in patients with rheumatoid arthritis: a multi-center parallel-group double-blind randomized controlled trial. |
| Q85272628 | Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis |
| Q36930704 | Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate |
| Q58204808 | Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs—a multicenter, double-blind, parallel-group trial |
| Q33726924 | Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register |
| Q35638208 | Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study |
| Q37258941 | Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials |
| Q34568533 | Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study) |
| Q40088333 | Efficacy and safety of sofosbuvir-based, interferon-free therapy : The Management of rheumatologic extrahepatic manifestations associated with chronic hepatitis C virus infection. |
| Q35636772 | Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study |
| Q43019736 | Efficacy and safety of tacrolimus in 101 consecutive patients with rheumatoid arthritis |
| Q33659249 | Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas |
| Q50044869 | Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis |
| Q50906224 | Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. |
| Q30401020 | Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases |
| Q34056237 | Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR) |
| Q47991516 | Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy |
| Q34768442 | Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). |
| Q33389401 | Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis |
| Q40086492 | Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized controlled open label study |
| Q41544189 | Efficacy of embedded nurse-led versus conventional physician-led follow-up in rheumatoid arthritis: a systematic review and meta-analysis |
| Q52839293 | Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis. |
| Q40169515 | Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials |
| Q59329010 | Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA |
| Q38993229 | Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis |
| Q92737334 | Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: real-world data from a university centre registry |
| Q56966850 | El bloqueo terapéutico del factor de necrosis tumoral disminuye la concentración sérica de interleucina 15 en pacientes con artritis reumatoide |
| Q36950780 | Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence |
| Q37712050 | Elevated Expression of Immunoreceptor Tyrosine-Based Inhibitory Motif (TIGIT) on T Lymphocytes is Correlated with Disease Activity in Rheumatoid Arthritis |
| Q36197198 | Elevated Neopterin Levels Are Associated with Increased Tuberculosis Risk in Rheumatoid Arthritis Patients with QuantiFERON Conversion during Biologic Therapy |
| Q42920234 | Elevated Serum Glucose-6-Phosphate Isomerase Correlates with Histological Disease Activity and Clinical Improvement After Initiation of Therapy in Patients with Rheumatoid Arthritis |
| Q84650982 | Elevated Serum Interleukin 33 Is Associated with Autoantibody Production in Patients with Rheumatoid Arthritis |
| Q84071185 | Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis |
| Q40823594 | Elevated autoantibodies against interleukin-17F correlate with disease activity in patients with early rheumatoid arthritis |
| Q41014256 | Elevated circulating Th17 and follicular helper CD4(+) T cells in patients with rheumatoid arthritis |
| Q36502693 | Elevated levels of T helper 17 cells are associated with disease activity in patients with rheumatoid arthritis |
| Q35636813 | Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells |
| Q44574975 | Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity |
| Q36013833 | Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy |
| Q35774189 | Endothelial progenitor cells in cardiovascular disease and chronic inflammation: from biomarker to therapeutic agent |
| Q36073831 | Enhanced activity of NLRP3 inflammasome in peripheral blood cells of patients with active rheumatoid arthritis |
| Q38543453 | Epidemiology research in rheumatology-progress and pitfalls. |
| Q34117122 | Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment. |
| Q41159831 | Epstein-Barr virus in peripheral blood is associated with response to rituximab therapy in rheumatoid arthritis patients |
| Q24795061 | Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious |
| Q50920498 | Evaluation in terms of dietary habits of rheumatic process: A clinical study. |
| Q64091799 | Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept |
| Q59684000 | Evaluation of Ascending Aorta Wall in Rheumatoid Arthritis by Tissue and Strain Doppler Imaging During Anti-Tumor Necrosis Factor-α Therapy |
| Q44337462 | Evaluation of Selected Rheumatoid Arthritis Activity Scores for Office-based Assessment |
| Q37294493 | Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis |
| Q90124749 | Evaluation of cytokine profiles in rheumatoid arthritis patients with clinically active disease and normal inflammatory indices |
| Q30566220 | Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience |
| Q51058021 | Evaluation of disease activity indices in Korean patients with rheumatoid arthritis. |
| Q41410246 | Evaluation of early rheumatoid arthritis disease activity and outcome |
| Q34349801 | Evaluation of efficacy of combination of methotrexate and hydroxychloroquine with leflunomide in active rheumatoid arthritis |
| Q88184732 | Evaluation of efficacy of infliximab for retinal vasculitis and extraocular symptoms in Behçet disease |
| Q34622578 | Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial |
| Q36414271 | Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition |
| Q40992087 | Evaluation of safety, efficacy and post-cessation efficacy durability of tocilizumab in patients with active rheumatoid arthritis |
| Q53226294 | Evaluation of the Choroid, Fovea, and Retinal Nerve Fiber Layer in Patients with Rheumatoid Arthritis. |
| Q54960379 | Evaluation of the Efficacy of Combined Therapy of Methotrexate and Etanercept versus Methotrexate as a Mono-Therapy. |
| Q48562919 | Evaluation of the association of UBASH3A and SYNGR1 with rheumatoid arthritis and disease activity and severity in Han Chinese |
| Q92840232 | Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study |
| Q36519316 | Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. |
| Q39032626 | Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial |
| Q88017399 | Evaluation of work disability in Japanese patients with rheumatoid arthritis: from the TOMORROW study |
| Q35637221 | Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. |
| Q38492012 | Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update |
| Q36983100 | Evidence that CXCL16 is a potent mediator of angiogenesis and is involved in endothelial progenitor cell chemotaxis : studies in mice with K/BxN serum-induced arthritis |
| Q36823811 | Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis |
| Q88915778 | Exercise is Associated With Increased Small HDL Particle Concentration and Decreased Vascular Stiffness in Rheumatoid Arthritis |
| Q35540004 | Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis |
| Q36133726 | Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis |
| Q33692177 | Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis |
| Q89099507 | Expression of Connexin 43 in Synovial Tissue of Patients With Rheumatoid Arthritis |
| Q38402453 | Expression of TNF-alpha and related signaling molecules in the peripheral blood mononuclear cells of rheumatoid arthritis patients. |
| Q34169452 | Expression of activating and inhibitory leukocyte immunoglobulin-like receptors in rheumatoid synovium: correlations to disease activity. |
| Q36791601 | Expression of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) on osteoclasts and its potential role in rheumatoid arthritis |
| Q33619665 | Extra-articular manifestations of rheumatoid arthritis: a hospital-based study. |
| Q50643092 | Extraarticular manifestations in Turkish patients with rheumatoid arthritis: impact of EAMs on the health-related quality of life in terms of disease activity, functional status, severity of pain, and social and emotional functioning. |
| Q92224140 | Extraction of Rheumatoid Arthritis Disease Activity Measures From Electronic Health Records Using Automated Processing Algorithms |
| Q83202778 | FK506 inhibition of gliostatin/thymidine phosphorylase production induced by tumor necrosis factor-α in rheumatoid fibroblast-like synoviocytes |
| Q38937827 | Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor |
| Q58003948 | Factors Associated with Severe Skin Infections in Patients Treated with Biologic Therapies for Inflammatory Rheumatic Diseases |
| Q33716784 | Factors associated with hand joint destruction in Chinese patients with rheumatoid arthritis |
| Q45251768 | Factors associated with time to diagnosis in early rheumatoid arthritis |
| Q48503161 | Factors influencing quality of life (QOL) for Korean patients with rheumatoid arthritis (RA). |
| Q47733654 | Factors influencing remission in rheumatoid arthritis patients: results from Karnataka rheumatoid arthritis comorbidity (KRAC) study |
| Q44098744 | Factors influencing the patient with rheumatoid arthritis in their decision to seek podiatry |
| Q97418887 | Factors that affect the assessment of the quality of life of rheumatoid arthritis patients depending on the prevalence of frailty syndrome |
| Q92347420 | Factors that influence rheumatologists' anti-tumor necrosis factor alpha prescribing decisions: a qualitative study |
| Q36927994 | Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis |
| Q39310980 | Falls and their association with physical tests, functional capacity, clinical and demographic factors in patients with rheumatoid arthritis |
| Q45911746 | Familial rheumatoid arthritis in patients referred to rheumatology clinics of Tabriz, Iran. |
| Q91584436 | Fasting triglycerides and glucose index: a useful screening test for assessing insulin resistance in patients diagnosed with rheumatoid arthritis and systemic lupus erythematosus |
| Q35987071 | Fatigue in Egyptian patients with rheumatic diseases: a qualitative study |
| Q33858474 | Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undiffere |
| Q90582693 | Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire: a cross-cultural adaptation and validation to the Turkish language |
| Q34633743 | Fears and beliefs in rheumatoid arthritis and spondyloarthritis: a qualitative study |
| Q58762147 | Features of patients with rheumatoid arthritis whose debut joint is a foot or ankle joint: A 5,479-case study from the IORRA cohort |
| Q40062767 | Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis |
| Q47775210 | Fibromyalgia remains a significant burden in rheumatoid arthritis patients in Australia |
| Q40710011 | Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy |
| Q24197686 | Fish oil supplements for rheumatoid arthritis |
| Q40054572 | Flares assessed weekly in patients with rheumatoid arthritis or axial spondyloarthritis and relationship with physical activity measured using a connected activity tracker: a 3-month study |
| Q90166578 | Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period |
| Q24312144 | Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients |
| Q28394552 | Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis |
| Q35620310 | Follistatin-like protein 1 is elevated in systemic autoimmune diseases and correlated with disease activity in patients with rheumatoid arthritis |
| Q90703379 | Folyl polyglutamate synthethase (FPGS) gene polymorphisms may influence methotrexate adverse events in South Indian Tamil Rheumatoid Arthritis patients |
| Q37345390 | Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis |
| Q85058997 | Foot pain in rheumatoid arthritis prevalence, risk factors and management: an epidemiological study |
| Q44180082 | Foot-related health care use in patients with rheumatoid arthritis in an outpatient secondary care center for rheumatology and rehabilitation in The Netherlands: a cohort study with a maximum of fifteen years of followup |
| Q37185644 | Footwear characteristics in people with inflammatory arthritis in Singapore |
| Q33873609 | Forefoot disease activity in rheumatoid arthritis patients in remission: results of a cohort study |
| Q35662919 | Forefoot pathology in rheumatoid arthritis identified with ultrasound may not localise to areas of highest pressure: cohort observations at baseline and twelve months |
| Q35605643 | Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity |
| Q51040537 | Fracture risk assessment and osteoporosis treatment disparities in 3,970 Japanese patients with rheumatoid arthritis. |
| Q35581083 | Free fatty acids are associated with insulin resistance but not coronary artery atherosclerosis in rheumatoid arthritis |
| Q44781663 | Frequencies of circulating IL-17-producing CD4+CD161+ T cells and CD4+CD161+ T cells correlate with disease activity in rheumatoid arthritis |
| Q86631230 | Frequency and predictors for falls in the ambulatory patients with rheumatoid arthritis: a longitudinal prospective study |
| Q34369334 | Frequency of Th17 CD4+ T cells in early rheumatoid arthritis: a marker of anti-CCP seropositivity |
| Q43868665 | Fucosylation of alpha1-acid glycoprotein (orosomucoid) compared with traditional biochemical markers of inflammation in recent onset rheumatoid arthritis |
| Q38304534 | Fucosylation of serum alpha1-acid glycoprotein in rheumatoid arthritis patients treated with infliximab |
| Q82252796 | Functional capacity in rheumatoid arthritis patients: comparison between Spanish and Brazilian sample |
| Q33873729 | Functional consequences of DECTIN-1 early stop codon polymorphism Y238X in rheumatoid arthritis |
| Q33629614 | Functional disability associated with disease and quality-of-life parameters in Chinese patients with rheumatoid arthritis |
| Q45953331 | Functional disability can deteriorate despite suppression of disease activity in patients with rheumatoid arthritis: a large observational cohort study. |
| Q34803070 | Functionally optimized orthoses for early rheumatoid arthritis foot disease: a study of mechanisms and patient experience |
| Q33793523 | Further optimization of the reliability of the 28-joint disease activity score in patients with early rheumatoid arthritis |
| Q55059683 | GITRL is associated with increased autoantibody production in patients with rheumatoid arthritis. |
| Q37177583 | GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate |
| Q92714965 | Galectin-1, -4, and -7 Were Associated with High Activity of Disease in Patients with Rheumatoid Arthritis |
| Q39991479 | Galectin-2 (LGALS2) 3279C/T polymorphism may be independently associated with diastolic blood pressure in patients with rheumatoid arthritis |
| Q90629137 | Galectin-9 gene (LGALS9) polymorphisms are associated with rheumatoid arthritis in Brazilian patients |
| Q64105948 | Gender Differences in Cardiovascular Risk Profile in Rheumatoid Arthritis Patients with Low Disease Activity |
| Q34361748 | Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study |
| Q47585110 | General characteristics of an early arthritis cohort in Argentina |
| Q48064243 | Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials. |
| Q38529234 | Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis |
| Q46496885 | Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism |
| Q36983069 | Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis: results from the treatment of early aggressive rheumatoid arthritis trial |
| Q35921093 | Genetics of serum concentration of IL-6 and TNFα in systemic lupus erythematosus and rheumatoid arthritis: a candidate gene analysis |
| Q58801649 | Genome-Wide Identification of N-Methyladenosine (mA) SNPs Associated With Rheumatoid Arthritis |
| Q28943301 | Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis |
| Q24647387 | Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis |
| Q28489093 | Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis |
| Q34886162 | Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci |
| Q40335127 | Genome-wide profiling in treatment-naive early rheumatoid arthritis reveals DNA methylome changes in T and B lymphocytes |
| Q33821370 | Ghrelin plasma levels, gastric ghrelin cell density and bone mineral density in women with rheumatoid arthritis |
| Q51363157 | Gingival crevicular fluid tissue/blood vessel-type plasminogen activator and plasminogen activator inhibitor-2 levels in patients with rheumatoid arthritis: effects of nonsurgical periodontal therapy. |
| Q42638844 | Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium |
| Q35637369 | Glucocorticoid resorption and influence on the hypothalamic-pituitary-adrenal axis after intra-articular treatment of the knee in resting and mobile patients |
| Q46681523 | Glucocorticoid therapy-induced memory deficits: acute versus chronic effects. |
| Q36757006 | Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study. |
| Q41523077 | Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. |
| Q92451394 | Glycosylation deficiency of lipopolysaccharide-binding protein and corticosteroid-binding globulin associated with activity and response to treatment for rheumatoid arthritis |
| Q24240895 | Golimumab for rheumatoid arthritis |
| Q36023494 | Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study |
| Q41517903 | Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study |
| Q34609376 | Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial |
| Q34637048 | Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160 |
| Q46585904 | Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial |
| Q37130039 | Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through |
| Q34601527 | Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study |
| Q37684575 | Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis |
| Q33750044 | HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis |
| Q52878524 | HLA class II alleles influence rheumatoid arthritis susceptibility and autoantibody status in South Indian Tamil population. |
| Q37593748 | HLA-DRB1 Amino Acid Positions 11/13, 71, and 74 Are Associated With Inflammation Level, Disease Activity, and the Health Assessment Questionnaire Score in Patients With Inflammatory Polyarthritis. |
| Q43605360 | HLA-DRB1 allele association with rheumatoid arthritis susceptibility and severity in Syria. |
| Q87741303 | HLA-DRB1 frequency in patients with familial and sporadic rheumatoid arthritis in north east of Iran |
| Q34418036 | Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: results from two UK inception cohorts |
| Q36392382 | Hand bone loss as an outcome measure in established rheumatoid arthritis: 2-year observational study comparing cortical and total bone loss |
| Q93050688 | Hand exercise for women with rheumatoid arthritis and decreased hand function: an exploratory randomized controlled trial |
| Q50226238 | Hand pains in women and men in early rheumatoid arthritis, a one year follow-up after diagnosis. The Swedish TIRA project |
| Q44906968 | Hand ultrasound: comparative study between "no rhupus" lupus erythematosus and rheumatoid arthritis. |
| Q33447156 | Handgrip strength measured by a dynamometer connected to a smartphone: a new applied health technology solution for the self-assessment of rheumatoid arthritis disease activity. |
| Q36334999 | Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assesso |
| Q36610390 | Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study |
| Q37465523 | Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial |
| Q48877928 | Health-related quality of life in rheumatoid arthritis: comparison of RAQoL with other scales in terms of disease activity, severity of pain, and functional status |
| Q51197412 | Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission. |
| Q50454132 | Hearing difficulties are common in patients with rheumatoid arthritis. |
| Q50316556 | Hearing impairment in patients with rheumatoid arthritis: association with anti-citrullinated protein antibodies. |
| Q44602690 | Heart rate, ejection duration and subendocardial viability ratio in patients with rheumatoid arthritis as compared to controls |
| Q50521608 | Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. |
| Q41912068 | Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy |
| Q34851473 | Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis |
| Q35753598 | Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH). |
| Q36255319 | High Concentrations of Angiopoietin-Like Protein 4 Detected in Serum from Patients with Rheumatoid Arthritis Can Be Explained by Non-Specific Antibody Reactivity |
| Q89099387 | High Disease Activity May Increase Fear-Avoidance Beliefs in Rheumatoid Arthritis |
| Q35760039 | High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis |
| Q58780906 | High Interleukin-37 (IL-37) Expression and Increased Mucin-Domain Containing-3 (TIM-3) on Peripheral T Cells in Patients with Rheumatoid Arthritis |
| Q50891600 | High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis. |
| Q39532345 | High frequency of vertebral fracture and low bone quality in patients with rheumatoid arthritis-Results from TOMORROW study |
| Q43852506 | High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study |
| Q30662067 | High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register |
| Q38719851 | High titer of anti-citrullinated peptide antibody is a risk factor for severe carotid atherosclerotic plaque in patients with rheumatoid arthritis: the TOMORROW study |
| Q47990735 | High-Frame-Rate Power Doppler Ultrasound Is More Sensitive than Conventional Power Doppler in Detecting Rheumatic Vascularisation |
| Q90372051 | High-resolution computed tomography of the lung in patients with rheumatoid arthritis: Prevalence of interstitial lung disease involvement and determinants of abnormalities |
| Q89579551 | Higher bodily adiposity, fat intake, and cholesterol serum levels are associated with higher disease activity in psoriatic arthritis patients: is there a link among fat and skin and joint involvement? |
| Q36733774 | Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgaris |
| Q37672346 | Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis |
| Q36937764 | Hip score and disease activity correlation in patients with rheumatoid arthritis after total hip arthroplasty |
| Q58555590 | Histamine Receptors and Cancer Pharmacology: An Update |
| Q24796830 | Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456] |
| Q46352659 | Host modulation in rheumatoid arthritis patients with TNF blockers significantly decreases biochemical parameters in periodontitis |
| Q34492067 | How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis |
| Q51827296 | Human cytomegalovirus pp65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice. |
| Q51058843 | Human leukocyte antigen-G polymorphism influences the age of onset and autoantibody status in rheumatoid arthritis. |
| Q37843179 | Human papillomavirus and chlamydia trachomatis infections in rheumatoid arthritis under anti-TNF therapy: an observational study |
| Q38825623 | Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping. |
| Q35215520 | Hypovitaminosis D in recent onset rheumatoid arthritis is predictive of reduced response to treatment and increased disease activity: a 12 month follow-up study |
| Q59042062 | Hypoxia induces mitochondrial mutagenesis and dysfunction in inflammatory arthritis |
| Q28727368 | IL-15 expression on RA synovial fibroblasts promotes B cell survival |
| Q46431837 | IL-22+ CD4+ T cells in patients with rheumatoid arthritis |
| Q37602033 | IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide |
| Q37394022 | IL-25 attenuates rheumatoid arthritis through suppression of Th17 immune responses in an IL-13-dependent manner |
| Q34117039 | Identification of RGS1 as a candidate biomarker for undifferentiated spondylarthritis by genome-wide expression profiling and real-time polymerase chain reaction |
| Q34346409 | Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. |
| Q51608422 | Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells. |
| Q58701938 | Identification of circular RNAs hsa_circ_0044235 in peripheral blood as novel biomarkers for rheumatoid arthritis |
| Q51260044 | Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. |
| Q47679541 | Identification of key genes for diabetic kidney disease using biological informatics methods |
| Q36968011 | Identification of novel urinary biomarkers for assessing disease activity and prognosis of rheumatoid arthritis |
| Q34075303 | Identification of urinary peptide biomarkers associated with rheumatoid arthritis |
| Q64102249 | IgG Anti-ghrelin Immune Complexes Are Increased in Rheumatoid Arthritis Patients Under Biologic Therapy and Are Related to Clinical and Metabolic Markers |
| Q48078207 | Illness perceptions and psychological distress associated with physical health-related quality of life in primary Sjögren's syndrome compared to systemic lupus erythematosus and rheumatoid arthritis |
| Q57025915 | Imbalance of circulating Tfr/Tfh ratio in patients with rheumatoid arthritis |
| Q37689761 | Immune response profiling in early rheumatoid arthritis: discovery of a novel interaction of treatment response with viral immunity. |
| Q52657156 | Immune-Mediated Inflammation Promotes Subclinical Atherosclerosis in Recent-Onset Psoriatic Arthritis Patients without Conventional Cardiovascular Risk Factors. |
| Q85523296 | Immunoglobulin subtypes predict therapy response to the biologics in patients with rheumatoid arthritis |
| Q42071582 | Immunophenotyping of rheumatoid arthritis reveals a linkage between HLA-DRB1 genotype, CXCR4 expression on memory CD4(+) T cells, and disease activity |
| Q35562353 | Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial |
| Q36005210 | Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). |
| Q34623922 | Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register |
| Q42210089 | Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO. |
| Q43981686 | Impact of fatigue on health-related quality of life in rheumatoid arthritis |
| Q35102134 | Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort |
| Q41521014 | Impact of midfoot and Hindfoot involvement on functional disability in Korean patients with rheumatoid arthritis |
| Q40588909 | Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial |
| Q34130318 | Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis |
| Q46267845 | Impact of secondhand smoking on disease activity in women with rheumatoid arthritis |
| Q39157244 | Impact of the size and number of swollen joints on serum C-reactive protein level and erythrocyte sedimentation rate in rheumatoid arthritis: a cross-sectional study in Japan |
| Q85118755 | Impact of tight control strategy on rheumatoid arthritis in Sarawak |
| Q37380288 | Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study |
| Q49825617 | Impact of vitamin D deficiency on clinical parameters in treatment-naïve rheumatoid arthritis patients |
| Q37719017 | Impaired Left Ventricular Diastolic Functions and Thickened Epicardial Adipose Tissue in Rheumatoid Arthritis Patients is Correlated with DAS-28 Score. |
| Q36903389 | Impaired beta cell function is present in nondiabetic rheumatoid arthritis patients |
| Q34553844 | Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study |
| Q33981303 | Improvement in symptoms and signs in the forefoot of patients with rheumatoid arthritis treated with anti-TNF therapy |
| Q41914520 | Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial |
| Q34017619 | Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies |
| Q40195611 | In rheumatoid arthritis, country of residence has an important influence on fatigue: results from the multinational COMORA study |
| Q42689640 | In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment |
| Q39371950 | In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study |
| Q51539744 | Inadequate Therapy Behavior Is Associated to Disease Flares in Patients With Rheumatoid Arthritis Who Have Achieved Remission With Disease-Modifying Antirheumatic Drugs |
| Q39154226 | Incidence and classification of cutaneous manifestations in rheumatoid arthritis |
| Q92708651 | Incidence and effect of insulin resistance on progression of atherosclerosis in rheumatoid arthritis patients of long disease duration |
| Q38896852 | Incidence and risk factors of fractures in patients with rheumatoid arthritis: an Asian prospective cohort study. |
| Q36321468 | Incidence of active mycobacterial infections in Brazilian patients with chronic inflammatory arthritis and negative evaluation for latent tuberculosis infection at baseline--a longitudinal analysis after using TNFa blockers |
| Q40061090 | Incidence of comprehensive hospitalization due to infection, cardiovascular disease, fractures, and malignancies in patients with rheumatoid arthritis |
| Q39797546 | Incidence rate of falls and its risk factors in patients with rheumatoid arthritis compared to controls: Four years of the TOMORROW study |
| Q44614377 | Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity? |
| Q80892742 | Increased CCR4 expression on circulating CD4(+) T cells in ankylosing spondylitis, rheumatoid arthritis and systemic lupus erythematosus |
| Q31038073 | Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort |
| Q37196901 | Increased IL-33 in synovial fluid and paired serum is associated with disease activity and autoantibodies in rheumatoid arthritis |
| Q90105320 | Increased IgA anti-citrullinated protein antibodies in the periodontal inflammatory exudate of healthy individuals compared to rheumatoid arthritis patients |
| Q88287470 | Increased arterial stiffness in rheumatoid arthritis and Its relation to disease activity: A cross sectional study |
| Q48030951 | Increased baseline RUNX2, caspase 3 and p21 gene expressions in the peripheral blood of disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy |
| Q33569373 | Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis. |
| Q37477058 | Increased expression of glucocorticoid receptor beta messenger RNA in patients with ankylosing spondylitis |
| Q54424759 | Increased expression of suppressor of cytokine signaling 1 mRNA in patients with rheumatoid arthritis. |
| Q34224709 | Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis |
| Q34614038 | Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study |
| Q51503196 | Increased myeloperoxidase plasma levels in rheumatoid arthritis. |
| Q51738030 | Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis? |
| Q36731722 | Increased responsiveness to toll-like receptor 4 stimulation in peripheral blood mononuclear cells from patients with recent onset rheumatoid arthritis |
| Q35617683 | Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy |
| Q42682599 | Incretins in patients with rheumatoid arthritis |
| Q37689920 | Independent associations of total and high molecular weight adiponectin with cardiometabolic risk and surrogate markers of enhanced early atherogenesis in black and white patients with rheumatoid arthritis: a cross-sectional study. |
| Q35108734 | Indicators of walking speed in rheumatoid arthritis: relative influence of articular, psychosocial, and body composition characteristics |
| Q46169259 | Indocyanine green-enhanced fluorescence optical imaging in patients with early and very early arthritis: a comparative study with magnetic resonance imaging |
| Q51597260 | Indoleamine 2,3-dioxygenase-expressing peripheral cells in rheumatoid arthritis and systemic lupus erythematosus: a cross-sectional study. |
| Q48178182 | Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. |
| Q56334428 | Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial |
| Q38195248 | Induction therapy with combination TNF inhibitor and methotrexate in early rheumatoid arthritis |
| Q44191676 | Inequities in access to biologic and synthetic DMARDs across 46 European countries |
| Q46760849 | Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment |
| Q37281848 | Inflammation and hypertension in rheumatoid arthritis |
| Q35819019 | Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technology |
| Q43539087 | Inflammation in dry eye associated with rheumatoid arthritis: cytokine and in vivo confocal microscopy study |
| Q37371379 | Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms |
| Q44958376 | Inflammatory burden interacts with conventional cardiovascular risk factors for carotid plaque formation in rheumatoid arthritis |
| Q26745646 | Inflammatory glycoproteins in cardiometabolic disorders, autoimmune diseases and cancer |
| Q46055310 | Inflammatory immune cell responses and Toll-like receptor expression in synovial tissues in rheumatoid arthritis patients treated with biologics or DMARDs |
| Q39888893 | Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial. |
| Q37037518 | Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE. |
| Q60049864 | Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results |
| Q37191464 | Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study |
| Q37245192 | Infliximab improves vascular stiffness in patients with rheumatoid arthritis |
| Q42955115 | Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience |
| Q59546338 | Infliximab therapy efficacy and persistence at a Canadian academic centre despite a change in access procedure |
| Q24798468 | Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study |
| Q34346418 | Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months |
| Q46598130 | Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients |
| Q92633591 | Influence of Ambient Air Pollution on Rheumatoid Arthritis Disease Activity Score Index |
| Q60448977 | Influence of Biological Therapeutics, Cytokines, and Disease Activity on Depression in Rheumatoid Arthritis |
| Q88964013 | Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis |
| Q37000208 | Influence of Insulin Resistance and TNF-α on the Inflammatory Process, Oxidative Stress, and Disease Activity in Patients with Rheumatoid Arthritis |
| Q28488365 | Influence of adult height on rheumatoid arthritis: association with disease activity, impairment of joint function and overall disability |
| Q44403988 | Influence of age and sex on functional outcome over time in a cohort of patients with recent-onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. |
| Q34110060 | Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register |
| Q34891374 | Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. |
| Q36095188 | Influence of bisphosphonate therapy on bone geometry, volumetric bone density and bone strength of femoral shaft in postmenopausal women with rheumatoid arthritis |
| Q45985880 | Influence of disease activity on the physical activity of rheumatoid arthritis patients. |
| Q47280323 | Influence of foot orthoses on plantar pressures, foot pain and walking ability of rheumatoid arthritis patients--a randomised controlled study |
| Q51140556 | Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry. |
| Q36226993 | Influence of periodontal treatment on rheumatoid arthritis: a systematic review and meta-analysis |
| Q45978454 | Influence of pregnancy on the adipocytokine and peroxisome proliferator-activated receptor pathways in peripheral blood mononuclear cells from healthy donors and rheumatoid arthritis patients. |
| Q84554453 | Influence of variations across the MMP-1 and -3 genes on the serum levels of MMP-1 and -3 and disease activity in rheumatoid arthritis |
| Q34805243 | Infrared sauna in patients with rheumatoid arthritis and ankylosing spondylitis. A pilot study showing good tolerance, short-term improvement of pain and stiffness, and a trend towards long-term beneficial effects |
| Q34132778 | Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes |
| Q54572361 | Inhibitory effect of tacrolimus on progression of joint damage in patients with rheumatoid arthritis. |
| Q52592137 | Inhibitory receptor expression on T cells as marker of disease activity and target to regulate effector cellular responses in Rheumatoid Arthritis. |
| Q36668191 | Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry |
| Q34237578 | Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study |
| Q36456346 | Insulin resistance and levels of adipokines in patients with untreated early rheumatoid arthritis |
| Q53035221 | Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. |
| Q33671233 | Insulin resistance is associated with increased concentrations of NT-proBNP in rheumatoid arthritis: IL-6 as a potential mediator |
| Q35897677 | Intelligent use and clinical benefits of electronic health records in rheumatoid arthritis |
| Q34104339 | Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis |
| Q34388610 | Interaction between smoking and HLA-DRB1*04 gene is associated with a high cardiovascular risk in Brazilian Amazon patients with rheumatoid arthritis |
| Q36245829 | Interaction between smoking and functional polymorphism in the TGFB1 gene is associated with ischaemic heart disease and myocardial infarction in patients with rheumatoid arthritis: a cross-sectional study |
| Q38748219 | Intercentre variance in patient reported outcomes is lower than objective rheumatoid arthritis activity measures: a cross-sectional study |
| Q46533955 | Interchangeability of 28-joint disease activity scores using the erythrocyte sedimentation rate or the C-reactive protein as inflammatory marker |
| Q54346251 | Interferon signals and monocytic sensitization of the interferon-γ signaling pathway in the peripheral blood of patients with rheumatoid arthritis. |
| Q28740658 | Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis |
| Q41103987 | Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study |
| Q51972906 | Interleukin-10 promoter polymorphism in patients with rheumatoid arthritis. |
| Q34154244 | Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression |
| Q35870921 | Interleukin-34 in rheumatoid arthritis: potential role in clinical therapy. |
| Q34343286 | Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy |
| Q53453418 | Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis. |
| Q37928726 | Interpreting clinical trial results for moderate-to-severe rheumatoid arthritis: practical applications for rheumatology healthcare providers |
| Q36492279 | Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis |
| Q34264322 | Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol. |
| Q24200961 | Interventions for periodontal disease in people with rheumatoid arthritis |
| Q35141922 | Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs? |
| Q39705167 | Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. |
| Q40340532 | Intravenous application of omega-3 fatty acids in patients with active rheumatoid arthritis. The ORA-1 trial. An open pilot study |
| Q24244815 | Intravenous immunoglobulin for juvenile idiopathic arthritis |
| Q36685781 | Intrinsic Brain Connectivity in Chronic Pain: A Resting-State fMRI Study in Patients with Rheumatoid Arthritis |
| Q48875369 | Inverse correlation of programmed death 1 (PD-1) expression in T cells to the spinal radiologic changes in Taiwanese patients with ankylosing spondylitis |
| Q36439978 | Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples |
| Q39341743 | Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage |
| Q42242252 | Investigation of clinical characteristics as predictive factors for the humoral immune response to the influenza vaccine in patients with rheumatoid arthritis |
| Q89099459 | Is 4-Hydroxynonenal a Predictive Parameter for the Development of Joint Erosion in Patients With Rheumatoid Arthritis? |
| Q57752907 | Is Citrullination Required for the Presence of Restricted Clonotypes Reacting With Type II Collagen? Comment on the Article by Chemin et al |
| Q44247481 | Is DAS28-CRP with three and four variables interchangeable in individual patients selected for biological treatment in daily clinical practice? |
| Q36172927 | Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis? |
| Q34054794 | Is There Any Relationship between Joint Destruction and Carotid Intima-media Thickness in Patients with Rheumatoid Arthritis? |
| Q87274572 | Is articular pain in rheumatoid arthritis correlated with ultrasound power Doppler findings? |
| Q51250784 | Is hand bone mineral density a marker for hand function in patients with established rheumatoid arthritis? The correlation among bone mineral density of the hand, radiological findings and hand function. |
| Q64066828 | Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts |
| Q37549902 | Is painless synovitis different from painful synovitis? A controlled, ultrasound, radiographic, clinical trial |
| Q36705720 | Is the frequency of metabolic syndrome higher in South Korean women with rheumatoid arthritis than in healthy subjects? |
| Q34033218 | Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints |
| Q95269473 | Joint remodeling outcome of serum levels of Dickkopf-1 (DKK1), cartilage oligomeric matrix protein (COMP), and C-telopeptide of type II collagen (CTXII) in rheumatoid arthritis |
| Q42957810 | Juvenile arthritis disease activity score is a better reflector of active disease than the disease activity score 28 in adults with polyarticular juvenile idiopathic arthritis. |
| Q38857615 | KPNA2 Contributes to the Inflammatory Processes in Synovial Tissue of Patients with Rheumatoid Arthritis and SW982 Cells |
| Q34803604 | Keishibukuryogan (gui-zhi-fu-ling-wan), a Kampo formula, decreases disease activity and soluble vascular adhesion molecule-1 in patients with rheumatoid arthritis |
| Q54459547 | Key findings towards optimising adalimumab treatment: the concentration-effect curve. |
| Q35999148 | Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy |
| Q44241112 | Knee joint destruction driven by residual local symptoms after anti-tumor necrosis factor therapy in rheumatoid arthritis |
| Q55005068 | Korean Red Ginseng exhibits no significant adverse effect on disease activity in patients with rheumatoid arthritis: a randomized, double-blind, crossover study. |
| Q34901953 | LDL cholesterolemia as a novel risk factor for radiographic progression of rheumatoid arthritis: a single-center prospective study |
| Q46246506 | LILRA5 is expressed by synovial tissue macrophages in rheumatoid arthritis, selectively induces pro-inflammatory cytokines and IL-10 and is regulated by TNF-alpha, IL-10 and IFN-gamma. |
| Q57558981 | LRP5 gene polymorphisms and radiographic joint damage in rheumatoid arthritis patients |
| Q45953403 | Lack association of body mass index with disease activity composites of rheumatoid arthritis in Korean population: cross-sectional observation. |
| Q44438694 | Lack of an association of GNB3 C825T polymorphism and blood pressure in patients with rheumatoid arthritis |
| Q35828195 | Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide |
| Q96304895 | Lack of association between clinical and ultrasound measures of disease activity in rheumatoid arthritis remission |
| Q37129611 | Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study. |
| Q35656020 | Lack of association of oral calcium supplementation with coronary artery calcification in rheumatoid arthritis |
| Q30494937 | Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study |
| Q42134953 | Large country differences in work outcomes in patients with RA - an analysis in the multinational study COMORA. |
| Q38854208 | Laryngeal involvement in juvenile idiopathic arthritis patients. |
| Q44828173 | Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. |
| Q34433298 | Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging |
| Q89282110 | Leptin as an obesity marker in rheumatoid arthritis |
| Q39890573 | Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. |
| Q50054302 | Leukocytapheresis in rheumatoid arthritis |
| Q33778590 | Level of inflammatory cytokines in rheumatoid arthritis patients: Correlation with 25-hydroxy vitamin D and reactive oxygen species |
| Q33482833 | Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis |
| Q53814762 | Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study. |
| Q43509736 | Levels of plasma fibrinogen are elevated in well-controlled rheumatoid arthritis |
| Q53127706 | Limited Value of the Multi-Biomarker Disease Activity Assay Compared to the Routine Assessment of Patient Index Data 3 (RAPID3) Score in the Prognosis of Important Clinical Outcomes in Rheumatoid Arthritis: Comment on the Article by Fleischmann et a |
| Q26859516 | Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis |
| Q47103006 | Lipocalin 2 as a clinical significance in rheumatoid arthritis. |
| Q34037325 | Lipoprotein subclasses determined by nuclear magnetic resonance spectroscopy and coronary atherosclerosis in patients with rheumatoid arthritis |
| Q40860005 | Lived Experiences of Sex Life Difficulties in Men and Women with Early RA - The Swedish TIRA Project |
| Q36475613 | Loci associated with N-glycosylation of human IgG are not associated with rheumatoid arthritis: a Mendelian randomisation study |
| Q47186021 | Logistic regression analysis of damp-heat and cold-damp impeding syndrome of rheumatoid arthritis: a perspective in Chinese medicine |
| Q34562870 | Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study |
| Q33725553 | Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients |
| Q88340678 | Long-Term Outcomes Following Achievement of Clinically Inactive Disease in Juvenile Idiopathic Arthritis: The Importance of Definition |
| Q47959078 | Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima-media thickness in female patients with active rheumatoid arthritis. |
| Q48517263 | Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice |
| Q45970934 | Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. |
| Q47720058 | Long-term efficacy of spa therapy in patients with rheumatoid arthritis. |
| Q50114940 | Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies |
| Q34289439 | Long-term health-enhancing physical activity in rheumatoid arthritis--the PARA 2010 study |
| Q37321296 | Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. |
| Q30811550 | Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment |
| Q37172675 | Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria |
| Q90146973 | Longitudinal Occurrence and Predictors of Patient-Provider Discordance Between Global Assessments of Disease Activity in Rheumatoid Arthritis: A Case-Control Study |
| Q34129848 | Longitudinal predictive ability of mapping models: examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients. |
| Q35489690 | Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis |
| Q57074018 | Losartan, but not Enalapril and Valsartan, Inhibits the Expression of IFN-γ, IL-6, IL-17F and IL-22 in PBMCs from Rheumatoid Arthritis Patients |
| Q38984869 | Loss of lean body mass affects low bone mineral density in patients with rheumatoid arthritis - results from the TOMORROW study. |
| Q42756280 | Low Prevalence of Nodules in Rheumatoid Arthritis Patients in Kuwait: A Description and a Comparison of Patients from the Kuwait Registry for Rheumatic Diseases |
| Q47687959 | Low body mass index is associated with impaired quality of life in patients with rheumatoid arthritis |
| Q35636544 | Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab. |
| Q33793453 | Low level of physical activity in women with rheumatoid arthritis is associated with cardiovascular risk factors but not with body fat mass--a cross sectional study |
| Q45769410 | Low prevalence of work disability in early inflammatory arthritis (EIA) and early rheumatoid arthritis at enrollment into a multi-site registry: results from the catch cohort |
| Q34654104 | Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis |
| Q36245964 | Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. |
| Q37704498 | Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. |
| Q36557712 | Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2) |
| Q34042476 | Low-field magnetic resonance imaging or combined ultrasonography and anti-cyclic citrullinated peptide antibody improve correct classification of individuals as established rheumatoid arthritis: results of a population-based, cross-sectional study |
| Q47401668 | Low-molecular-weight adiponectin is more closely associated with disease activity of rheumatoid arthritis than other adiponectin multimeric forms |
| Q39371943 | Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study |
| Q51808399 | Lower urinary tract symptoms in female patients with rheumatoid arthritis. |
| Q55057359 | M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis. |
| Q35605418 | MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial |
| Q34916347 | MRI bone oedema scores are higher in the arthritis mutilans form of psoriatic arthritis and correlate with high radiographic scores for joint damage |
| Q53370209 | MRI evidence of persistent joint inflammation and progressive joint damage despite clinical remission during treatment of early rheumatoid arthritis. |
| Q38200013 | MRI in rheumatoid arthritis: a useful tool for the clinician? |
| Q82436355 | MRI of the transverse and alar ligaments in rheumatoid arthritis: feasibility and relations to atlantoaxial subluxation and disease activity |
| Q46225217 | MTRR A66G, RFC1 G80A, and MTHFR C677T and A1298C Polymorphisms and Disease Activity in Mexicans with Rheumatoid Arthritis Treated with Methotrexate |
| Q34486477 | Macrophage activation and coronary atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis |
| Q36933138 | Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. |
| Q36204145 | Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritis. |
| Q39215532 | Magnetic Resonance Imaging-Detected Myocardial Inflammation and Fibrosis in Rheumatoid Arthritis: Associations With Disease Characteristics and N-Terminal Pro-Brain Natriuretic Peptide Levels |
| Q47094309 | Magnetic resonance imaging of the hand and wrist in a randomized, double-blind, multicenter, placebo-controlled trial of infliximab for rheumatoid arthritis: Comparison of dynamic contrast enhanced assessments with semi-quantitative scoring. |
| Q41454498 | Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, |
| Q34152994 | Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments |
| Q48330154 | Major trends in the manifestations and treatment of rheumatoid arthritis in a multiethnic cohort in Singapore |
| Q55407299 | Male patients with rheumatoid arthritis have an increased risk of osteoporosis: Frequency and risk factors. |
| Q80632200 | Malnutrition in women with rheumatoid arthritis is not revealed by clinical anthropometrical measurements or nutritional evaluation tools |
| Q33793383 | Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis |
| Q38308454 | Management of juvenile idiopathic arthritis: hitting the target |
| Q46848758 | Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment |
| Q35699212 | Management of rheumatoid arthritis: summary of NICE guidance. |
| Q31043286 | Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for [...] |
| Q37270882 | Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study |
| Q64247847 | Mass spectrometry-based analysis of cerebrospinal fluid from arthritis patients-immune-related candidate proteins affected by TNF blocking treatment |
| Q36907694 | Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort |
| Q50110839 | Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis |
| Q38072667 | Maximizing early treatment with biologics in patients with rheumatoid arthritis: the ultimate breakthrough in joints preservation |
| Q38647845 | Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate |
| Q82470983 | Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-α therapy |
| Q34057574 | Measure of function in rheumatoid arthritis: individualised or classical scales? |
| Q24805412 | Measurement of global functional performance in patients with rheumatoid arthritis using rheumatology function tests |
| Q38019622 | Measures in rheumatoid arthritis: are we measuring too many parameters |
| Q35687818 | Measures of rheumatoid arthritis disease activity in Australian clinical practice |
| Q34269994 | Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index [...] |
| Q33234551 | Measuring disease activity for rheumatoid arthritis |
| Q48610087 | Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analy |
| Q37207129 | Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability |
| Q33873068 | Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. |
| Q39043284 | Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients |
| Q84617398 | Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome |
| Q37023883 | Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis |
| Q31116097 | Metabolic syndrome in rheumatoid arthritis: case control study |
| Q50957777 | Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. |
| Q39367839 | Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. |
| Q37227519 | Metabolomics profiling of the free and total oxidised lipids in urine by LC-MS/MS: application in patients with rheumatoid arthritis |
| Q42734608 | Methodological issues in the design of a rheumatoid arthritis activity score and its cut-offs |
| Q50283343 | Methotrexate Restores Regulatory T Cell Function Through Demethylation of the FoxP3 Upstream Enhancer in Patients With Rheumatoid Arthritis. |
| Q55401837 | Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritis. |
| Q43810717 | Methotrexate compliance among patients with rheumatoid arthritis: the influence of disease activity, disease duration, and co-morbidity in a 10-year longitudinal study |
| Q94336562 | Methotrexate for psoriatic arthritis |
| Q35636960 | Methotrexate modulates the kinetics of adenosine in humans in vivo |
| Q24202055 | Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis |
| Q38939820 | Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. |
| Q24235784 | Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis |
| Q44050282 | Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis |
| Q37350896 | Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study |
| Q41718646 | Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study. |
| Q42626987 | Metrologic properties of ultrasound versus clinical evaluation of synovitis in rheumatoid arthritis: results of a multicenter, randomized study |
| Q90236306 | MicroRNA-132, miR-146a, and miR-155 as potential biomarkers of methotrexate response in patients with rheumatoid arthritis |
| Q39882466 | Microalbuminuria in rheumatoid arthritis in the post penicillamine/gold era: association with hypertension, but not therapy or inflammation. |
| Q33869938 | Microvascular function is preserved in newly diagnosed rheumatoid arthritis and low systemic inflammatory activity |
| Q57464166 | Minimal Clinically Important Improvement of Routine Assessment of Patient Index Data 3 in Rheumatoid Arthritis |
| Q98830298 | Model-Based Meta-analysis Compares DAS28 Rheumatoid Arthritis Treatment Effects and Suggests an Expedited Trial Design for Early Clinical Development |
| Q46456972 | Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency |
| Q39168790 | Modelling outcomes of complex treatment strategies following a clinical guideline for treatment decisions in patients with rheumatoid arthritis. |
| Q33651231 | Models solely using claims-based administrative data are poor predictors of rheumatoid arthritis disease activity |
| Q90321904 | Modified Disease Activity Score at 3 Months Is a Significant Predictor for Rapid Radiographic Progression at 12 Months Compared With Other Measures in Patients With Rheumatoid Arthritis |
| Q36204149 | Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis |
| Q37602700 | Molecular alterations in skeletal muscle in rheumatoid arthritis are related to disease activity, physical inactivity, and disability |
| Q36790328 | Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept |
| Q37939610 | Molecular imaging of cartilage damage of finger joints in early rheumatoid arthritis with delayed gadolinium-enhanced magnetic resonance imaging. |
| Q50951616 | Monocarboxylate transporter 4, associated with the acidification of synovial fluid, is a novel therapeutic target for inflammatory arthritis. |
| Q33516229 | Monocyte scintigraphy in rheumatoid arthritis: the dynamics of monocyte migration in immune-mediated inflammatory disease |
| Q50964701 | Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. |
| Q64903677 | Morning melatonin serum values do not correlate with disease activity in rheumatoid arthritis: a cross-sectional study. |
| Q34658023 | Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab |
| Q47272022 | Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register |
| Q42955860 | Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count |
| Q90588166 | Motion analysis of the wrist joints in Chinese rheumatoid arthritis patients: a cross-sectional study |
| Q34449612 | Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient's perspective |
| Q40564193 | Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome |
| Q54962371 | Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. |
| Q33645362 | Multi-dimensional health assessment questionnaire in China: reliability, validity and clinical value in patients with rheumatoid arthritis |
| Q61136608 | Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission |
| Q36696967 | Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia |
| Q55455487 | Multidisciplinary recommendations for diagnosis and treatment of foot problems in people with rheumatoid arthritis. |
| Q38632017 | Multidisciplinary team care for people with rheumatoid arthritis: a systematic review and meta-analysis |
| Q36464831 | Muscle density in rheumatoid arthritis: associations with disease features and functional outcomes |
| Q35636564 | Muscle strength, pain, and disease activity explain individual subdimensions of the Health Assessment Questionnaire disability index, especially in women with rheumatoid arthritis |
| Q26829955 | My treatment approach to rheumatoid arthritis |
| Q38959553 | Mycoplasmal lipid-associated membrane proteins and Mycoplasma arthritidis mitogen recognition by serum antibodies from patients with rheumatoid arthritis. |
| Q58574869 | Myocardial Inflammation, Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (FDG PET-CT) is Associated with Disease Activity in Rheumatoid Arthritis |
| Q33695937 | Myocardial Perfusion in Rheumatoid Arthritis Patients: Associations with Traditional Risk Factors and Novel Biomarkers |
| Q44290205 | NADPH oxidase priming and p47phox phosphorylation in neutrophils from synovial fluid of patients with rheumatoid arthritis and spondylarthropathy |
| Q61946754 | NOD2 allele variants in patients with rheumatoid arthritis |
| Q41687175 | Nardilysin is involved in autoimmune arthritis via the regulation of tumour necrosis factor alpha secretion |
| Q36993245 | Natural autoantibodies reactive with glycosaminoglycans in rheumatoid arthritis. |
| Q42694478 | Negative and positive illness representations of rheumatoid arthritis: a latent profile analysis |
| Q51119389 | Net cholesterol efflux capacity of HDL enriched serum and coronary atherosclerosis in rheumatoid arthritis. |
| Q88751451 | Neuromuscular Electrical Stimulation Compared to Volitional Exercise for Improving Muscle Function in Rheumatoid Arthritis: A Randomized Pilot Study |
| Q84598859 | Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks? |
| Q79712749 | No effects of adalimumab therapy on the activation of NF-kappaB in lymphocytes from patients with severe rheumatoid arthritis |
| Q89460021 | No evidence of abnormal metabolic or inflammatory activity in the brains of patients with rheumatoid arthritis: results from a preliminary study using whole-brain magnetic resonance spectroscopic imaging (MRSI) |
| Q34699641 | No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register |
| Q44553220 | No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan |
| Q53169655 | No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study. |
| Q37662723 | Non-medical costs during the first year after diagnosis in two cohorts of patients with early rheumatoid arthritis, enrolled 10 years apart |
| Q35193842 | Novel insights into the regulatory architecture of CD4+ T cells in rheumatoid arthritis |
| Q61628116 | Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data |
| Q56967231 | Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis |
| Q44911303 | Nutrient supplementation with polyunsaturated fatty acids and micronutrients in rheumatoid arthritis: clinical and biochemical effects |
| Q89099319 | Obesity Associated With Active, but Preserved Joints in Rheumatoid Arthritis: Results From our National Registry |
| Q79882239 | Obesity is independently associated with impaired quality of life in patients with rheumatoid arthritis |
| Q33438685 | Objective assessment of abnormal gait in patients with rheumatoid arthritis using a smartphone |
| Q28245986 | Ocrelizumab: a step forward in the evolution of B-cell therapy |
| Q35540009 | Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial |
| Q37010967 | Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient? |
| Q48302611 | Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up |
| Q51474223 | Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. |
| Q45350015 | Oral health-related quality of life among outpatients with rheumatoid arthritis |
| Q42276761 | Orchestration of inflammation and adaptive immunity in Borrelia burgdorferi-induced arthritis by neutrophil-activating protein A. |
| Q48057339 | Oro-facial evaluation of women with rheumatoid arthritis. |
| Q82732857 | Osteoporosis in psoriatic arthritis: is there any? |
| Q35612713 | Osteoprotegerin Polymorphisms in a Mexican Population with Rheumatoid Arthritis and Generalized Osteoporosis: A Preliminary Report |
| Q37619717 | Outcome measures in inflammatory rheumatic diseases |
| Q57169494 | Outcome measures in rheumatoid arthritis: the OMERACT process |
| Q36375678 | Outcome of patients with autoimmune diseases in the intensive care unit: a mixed cluster analysis |
| Q36398152 | Outcome of rheumatoid arthritis following adjunct statin therapy |
| Q47190952 | Outcome of transition phase patients with juvenile idiopathic arthritis. |
| Q33892353 | Outcome predictors of intra-articular glucocorticoid treatment for knee synovitis in patients with rheumatoid arthritis - a prospective cohort study |
| Q48372838 | Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation. |
| Q57224067 | Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis |
| Q46921988 | Oxidative stress in rheumatoid arthritis patients: relationship to diseases activity |
| Q51401255 | Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. |
| Q46889098 | Oxygen cost of walking, physical activity, and sedentary behaviours in rheumatoid arthritis |
| Q37435917 | PADI4 haplotypes in association with RA Mexican patients, a new prospect for antigen modulation |
| Q54332329 | PAI-1 mRNA expression and plasma level in rheumatoid arthritis: relationship with 4G/5G PAI-1 polymorphism. |
| Q57486489 | PD-L1 Regulatory B Cells Are Significantly Decreased in Rheumatoid Arthritis Patients and Increase After Successful Treatment |
| Q38097709 | PROMs in inflammatory arthritis: moving from static to dynamic. |
| Q39809621 | PRTX-100 and methotrexate in patients with active rheumatoid arthritis: A Phase Ib randomized, double-blind, placebo-controlled, dose-escalation study |
| Q48052143 | Pain and difficulties performing valued life activities in women and men with rheumatoid arthritis |
| Q56803208 | Pain coping and social support as predictors of long-term functional disability and pain in early rheumatoid arthritis |
| Q38056432 | Pain in rheumatoid arthritis |
| Q35537108 | Parity, time since last live birth and long-term functional outcome: a study of women participating in the Norfolk Arthritis Register |
| Q36167063 | Pathogenic Transdifferentiation of Th17 Cells Contribute to Perpetuation of Rheumatoid Arthritis during Anti-TNF Treatment |
| Q54595969 | Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis. |
| Q35808064 | Patient Acceptable Symptom State in Self-Report Questionnaires and Composite Clinical Disease Index for Assessing Rheumatoid Arthritis Activity: Identification of Cut-Off Points for Routine Care |
| Q47574826 | Patient and partner dispositional optimism as a long-term predictor of illness representations in autoimmune diseases. |
| Q51726032 | Patient demographics and disease variables correlate with distinct cytokine patterns in mitogen-stimulated peripheral blood mononuclear cells from rheumatoid arthritis patients. |
| Q35636868 | Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial |
| Q50600440 | Patient self-assessment of flare in rheumatoid arthritis: criterion and concurrent validity of the Flare instrument. |
| Q34997800 | Patient's access to healthcare and treatment in rheumatoid arthritis: the views of stakeholders in Portugal. |
| Q37065115 | Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent? |
| Q41595008 | Patient's perspective of sustained remission in rheumatoid arthritis |
| Q39330884 | Patient- and clinician-reported outcomes for patients with new presentation of inflammatory arthritis: observations from the National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis |
| Q38802434 | Patient-Physician Discordance in Global Assessment in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis |
| Q38822369 | Patient-Reported Outcomes in Psoriatic Arthritis. |
| Q35372388 | Patient-centered psoriatic arthritis (PsA) activity assessment by Stockerau Activity Score for Psoriatic Arthritis (SASPA). |
| Q33910513 | Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis |
| Q41670046 | Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation |
| Q50197648 | Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis: Results from the Yorkshire Early Arthritis Register |
| Q34803148 | Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial |
| Q38910063 | Patient-reported outcomes as predictors of remission in early rheumatoid arthritis patients treated with tight control treat-to-target approach. |
| Q48046367 | Patient-self assessment of flare in rheumatoid arthritis: translation and reliability of the Flare instrument |
| Q37150367 | Patients with Rheumatoid Arthritis and Chronic Pain Display Enhanced Alpha Power Density at Rest |
| Q35769101 | Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2. |
| Q41919476 | Patients with rheumatoid arthritis have better functional and working ability but poorer general health and higher comorbidity rates today than in the late 1990s |
| Q49155438 | Patients' perceptions of health-related quality of life in rheumatoid arthritis |
| Q34340013 | Pattern of Young and Old Onset Rheumatoid Arthritis (YORA and EORA) Among a Group of Egyptian Patients with Rheumatoid Arthritis |
| Q33545673 | Pattern-based diagnosis and screening of differentially expressed serum proteins for rheumatoid arthritis by proteomic fingerprinting |
| Q39020448 | Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis. |
| Q40504454 | Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate |
| Q50533824 | Pentraxin 3 in serum and synovial fluid of patients with rheumatoid arthritis with and without autoantibodies. |
| Q46743986 | Perceived functional disabilities among rheumatoid arthritis patients |
| Q33413162 | Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline |
| Q35702552 | Perceptions of physical activity engagement among adults with rheumatoid arthritis and rheumatologists |
| Q40001370 | Perceptions of the Cause, Impact and Management of Persistent Fatigue in Patients with Rheumatoid Arthritis Following Tumour Necrosing Factor Inhibition Therapy. |
| Q36317874 | Performance evaluation of FlowCytomix assays to quantify cytokines in patients with rheumatoid arthritis |
| Q30821758 | Performance of Routine Assessment of Patient Index Data 3 (RAPID3) for assessment of rheumatoid arthritis in clinical practice: differential agreement of RAPID3 according to disease activity categories |
| Q42010067 | Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study |
| Q31104875 | Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data |
| Q31038425 | Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors |
| Q30539881 | Performance of the Dutch SF-36 version 2 as a measure of health-related quality of life in patients with rheumatoid arthritis |
| Q60952997 | Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validation |
| Q35249630 | Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria |
| Q48287493 | Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients. |
| Q64994712 | Periodontal Health and Oral Microbiota in Patients with Rheumatoid Arthritis. |
| Q43892762 | Periodontal condition of patients with autoimmune diseases and the effect of anti-tumor necrosis factor-α therapy |
| Q55265895 | Periodontal disease influences osteoclastogenic bone markers in subjects with and without rheumatoid arthritis. |
| Q41065857 | Periodontal pathogens participate in synovitis in patients with rheumatoid arthritis in clinical remission: a retrospective case-control study |
| Q33907384 | Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors |
| Q33970887 | Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis |
| Q37627252 | Periodontitis in early and chronic rheumatoid arthritis: a prospective follow-up study in Finnish population |
| Q36633230 | Periodontitis in established rheumatoid arthritis patients: a cross-sectional clinical, microbiological and serological study |
| Q36140339 | Peripheral inflammatory disease associated with centrally activated IL-1 system in humans and mice |
| Q50599640 | Persistence of Disease-Associated Anti-Citrullinated Protein Antibody-Expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission. |
| Q37206976 | Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register |
| Q40502497 | Persistently active disease is common in patients with rheumatoid arthritis, particularly in women: a long-term inception cohort study. |
| Q43788885 | Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects |
| Q61447149 | Personality, depression and anxiety in primary Sjogren's syndrome - Association with sociodemographic factors and comorbidity |
| Q48260930 | Personalized diet and exercise recommendations in early rheumatoid arthritis: A feasibility trial |
| Q38084444 | Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine |
| Q88790397 | Pharmacogenomics in the treatment of rheumatoid arthritis: clinical implication and perspective |
| Q35814091 | Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted? |
| Q92451152 | Pharmacological conditioning in the treatment of recent-onset rheumatoid arthritis: a randomized controlled trial study protocol |
| Q59137786 | Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate |
| Q47918450 | Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis |
| Q38944886 | Phenome-Wide Association Study of Rheumatoid Arthritis Subgroups Identifies Association Between Seronegative Disease and Fibromyalgia |
| Q91555207 | Phenotypic and functional characterization of natural killer cells in rheumatoid arthritis-regulation with interleukin-15 |
| Q36800150 | Phenotypic, Functional, and Gene Expression Profiling of Peripheral CD45RA+ and CD45RO+ CD4+CD25+CD127(low) Treg Cells in Patients With Chronic Rheumatoid Arthritis |
| Q28298650 | Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells |
| Q48319373 | Physical Activity Assessment Using an Activity Tracker in Patients with Rheumatoid Arthritis and Axial Spondyloarthritis: Prospective Observational Study. |
| Q47874353 | Physical Activity and Correlates of Physical Activity Participation Over Three Years in Adults With Rheumatoid Arthritis |
| Q35204815 | Physical activity measured by the SenseWear Armband in women with rheumatoid arthritis |
| Q48973960 | Physical-activity coaching and health status in rheumatoid arthritis: a person-oriented approach |
| Q38533964 | Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden |
| Q91971783 | Plasma MicroRNAs in Established Rheumatoid Arthritis Relate to Adiposity and Altered Plasma and Skeletal Muscle Cytokine and Metabolic Profiles |
| Q36580833 | Plasma and Synovial Fluid TrxR Levels are Correlated With Disease Risk and Severity in Patients With Rheumatoid Arthritis |
| Q28538381 | Plasma levels of IL-37 and correlation with TNF-α, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis |
| Q46817487 | Plasma osteopontin is correlated with bone resorption markers in rheumatoid arthritis patients |
| Q84596969 | Plasma soluble IL-6 receptor concentration in rheumatoid arthritis: associations with the rs8192284 IL6R polymorphism and with disease activity |
| Q92965038 | Platelet/Lymphocyte, Lymphocyte/Monocyte, and Neutrophil/Lymphocyte Ratios as Biomarkers in Patients with Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease |
| Q34981525 | Platelets induce a proinflammatory phenotype in monocytes via the CD147 pathway in rheumatoid arthritis |
| Q39140572 | Pleiotrophin, the angiogenic and mitogenic growth factor: levels in serum and synovial fluid in rheumatoid arthritis and osteoarthritis : And correlation with clinical, laboratory and radiological indices |
| Q35637930 | Polymorphism at position +896 of the toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritis |
| Q80463829 | Polymorphism in the tumor necrosis factor-alpha gene promoter is associated with severity of rheumatoid arthritis in the Czech population |
| Q39089883 | Polymorphism in vitamin D receptor and osteoprotegerin genes in Egyptian rheumatoid arthritis patients with and without osteoporosis |
| Q49915054 | Polymorphisms and expression of inflammasome genes are associated with the development and severity of rheumatoid arthritis in Brazilian patients |
| Q40065488 | Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis |
| Q34896529 | Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind? |
| Q90226161 | Porphyromonas gingivalis in the tongue biofilm is associated with clinical outcome in rheumatoid arthritis patients |
| Q45792506 | Positive synovial vascularity in patients with low disease activity indicates smouldering inflammation leading to joint damage in rheumatoid arthritis: time-integrated joint inflammation estimated by synovial vascularity in each finger joint |
| Q51871560 | Positiveness of purified protein derivatives in rheumatoid arthritis patients who are not receiving immunosuppressive therapy. |
| Q88489409 | Possible use of miRNAs-146a and -499 expression and their polymorphisms as diagnostic markers for rheumatoid arthritis |
| Q35154359 | Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis |
| Q36981540 | Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis |
| Q37296393 | Potential role of interleukin-18 in patients with rheumatoid arthritis-associated carotid intima-media thickness but not insulin resistance |
| Q59799935 | Potential role of platelets for atherosclerotic events in rheumatoid arthritis |
| Q35638115 | Power Doppler sonography monitoring of synovial perfusion at the wrist joints in patients with rheumatoid arthritis treated with adalimumab |
| Q41168364 | Power of national economy, disease control and employment status in patients with RA-an analytical multi-site ecological study |
| Q41773090 | Pre-analytical effects of blood sampling and handling in quantitative immunoassays for rheumatoid arthritis |
| Q34688901 | Pre-treatment whole blood gene expression is associated with 14-week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab-treated rheumatoid arthritis patients |
| Q42956746 | Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate |
| Q41917636 | Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial |
| Q93384223 | Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study |
| Q80148309 | Predicting factors for severity of rheumatoid arthritis: a prospective multicenter cohort study of 172 patients over 3 years |
| Q93192331 | Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models |
| Q41026649 | Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. |
| Q33747444 | Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms |
| Q34131674 | Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines |
| Q55655944 | Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). |
| Q52859192 | Prediction of the therapeutic response to methotrexate at 24 weeks by methotrexate-polyglutamates concentration in erythrocytes at 8 weeks in patients with rheumatoid arthritis. |
| Q57471049 | Prediction of treatment response in rheumatoid arthritis patients using genome-wide SNP data |
| Q41015565 | Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis Patients |
| Q92931974 | Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment |
| Q37165244 | Predictors of change in bodily pain in early rheumatoid arthritis: an inception cohort study |
| Q33715046 | Predictors of depression in a multiethnic cohort of patients with rheumatoid arthritis. |
| Q44832625 | Predictors of endothelial dysfunction in patients with rheumatoid arthritis |
| Q49040453 | Predictors of functional impairment and pain in erosive osteoarthritis of the interphalangeal joints: comparison with controlled inflammatory arthritis |
| Q38654773 | Predictors of health care drop-out in an inception cohort of patients with early onset rheumatoid arthritis. |
| Q39492734 | Predictors of pain for patients with early inflammatory polyarthritis |
| Q89876454 | Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis |
| Q58134151 | Presarcopenia and its Impact on Disability in Female Patients With Rheumatoid Arthritis |
| Q36955351 | Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project |
| Q48069664 | Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis |
| Q35016743 | Present role of positron emission tomography in the diagnosis and monitoring of peripheral inflammatory arthritis: a systematic review. |
| Q35605424 | Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial |
| Q44251450 | Prevalence and risk factors associated with low-impact fractures in men with rheumatoid arthritis |
| Q41466368 | Prevalence of dyslipidemia in Japanese patients with rheumatoid arthritis and effects of atorvastatin treatment |
| Q90042742 | Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study |
| Q37230942 | Prevalence of foot problems in people with inflammatory arthritis in Singapore |
| Q35809711 | Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy. |
| Q40961678 | Prevalence of hypothyroidism in rheumatoid arthritis and its correlation with disease activity |
| Q51065360 | Prevalence of sexual dysfunction among female patients followed in a Brasília Cohort of early rheumatoid arthritis. |
| Q36511541 | Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis |
| Q35185494 | Prevalence, incidence and characteristics of the metabolic syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs: the complex relationship between MetS and |
| Q58204736 | Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study |
| Q37200651 | Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort |
| Q36243974 | Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects |
| Q34082035 | Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study. |
| Q51153493 | Prognostic Factors of Radiological Damage in Rheumatoid Arthritis: A 10-year Retrospective Study |
| Q61863540 | Prognostic value of Th1/Th2 ratio in rheumatoid arthritis |
| Q90454106 | Prognostic value of comorbidity indices and lung diseases in early rheumatoid arthritis: a UK population-based study |
| Q33196212 | Programmed cell death in rheumatoid arthritis peripheral blood T-cell subpopulations determined by laser scanning cytometry. |
| Q37690404 | Progression of coronary artery atherosclerosis in rheumatoid arthritis: comparison with participants from the Multi-Ethnic Study of Atherosclerosis |
| Q79347849 | Proposal for a sonographic classification of target joints in rheumatoid arthritis |
| Q84594201 | Proposing a method of regional assessment and a novel outcome measure in rheumatoid arthritis |
| Q58728255 | Prospective assessment of cardiovascular risk parameters in patients with rheumatoid arthritis |
| Q28743224 | Prostaglandin E2 synthesizing enzymes in rheumatoid arthritis B cells and the effects of B cell depleting therapy on enzyme expression |
| Q38251801 | Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives |
| Q91826148 | Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients |
| Q35899148 | Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis |
| Q26786781 | Proteomics in Rheumatoid Arthritis Research |
| Q40145642 | Proteomics to predict the response to tumour necrosis factor-α inhibitors in rheumatoid arthritis using a supervised cluster-analysis based protein score |
| Q40218228 | Psoriasis and psoriatic arthritis in African-American patients--the need to measure disease burden |
| Q38668527 | Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study |
| Q65001565 | Psychological affection in rheumatoid arthritis patients in relation to disease activity. |
| Q40366204 | Psychological distress and personality traits in early rheumatoid arthritis: A preliminary survey |
| Q33716790 | Psychometric properties of the painDETECT questionnaire in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Rasch analysis and test-retest reliability |
| Q36406749 | Psychometric properties of three single-item pain scales in patients with rheumatoid arthritis seen during routine clinical care: a comparative perspective on construct validity, reproducibility and internal responsiveness |
| Q31043299 | Psychophysiological responses to stress after stress management training in patients with rheumatoid arthritis |
| Q39686381 | Psychosocial problems among newly diagnosed rheumatoid arthritis patients. |
| Q53293292 | Pulmonary involvement in early rheumatoid arthritis patients. |
| Q53456694 | Pulmonary involvement in patients with early rheumatoid arthritis. |
| Q35673147 | Putative IL-10 Low Producer Genotypes Are Associated with a Favourable Etanercept Response in Patients with Rheumatoid Arthritis |
| Q36204125 | QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries |
| Q35585144 | Quality measurement and improvement in rheumatology: rheumatoid arthritis as a case study |
| Q40401339 | Quality of life and costs for different treatment strategies for rheumatoid arthritis |
| Q81198316 | Quality of life in Indian patients with rheumatoid arthritis |
| Q48447723 | Quality of life in patients with Takayasu's arteritis is impaired and comparable with rheumatoid arthritis and ankylosing spondylitis patients. |
| Q36290134 | Quality of life in rheumatoid arthritis |
| Q44213104 | Quantification and Impact of Secondary Osteoarthritis in Patients With Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis |
| Q92136836 | Quantifying disease activity in rheumatoid arthritis with the TSPO PET ligand 18F-GE-180 and comparison with 18F-FDG and DCE-MRI |
| Q37690281 | Quantitative assessment of synovitis in patients with rheumatoid arthritis using fluorescence optical imaging. |
| Q36780940 | Quantitative measures to assess patients with rheumatic diseases: 2006 update |
| Q33870130 | RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural |
| Q39061308 | RAPID3 scores and hand outcome measurements in RA patients: a preliminary study |
| Q35159896 | RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies |
| Q40377000 | ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany |
| Q35204743 | Racial and ethnic disparities in disease activity and function among persons with rheumatoid arthritis from university-affiliated clinics. |
| Q35637808 | Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis |
| Q41478116 | Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study |
| Q34607591 | Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placeb |
| Q53085402 | Radiographic prognosis of finger joint damage predicted by early alteration in synovial vascularity in patients with rheumatoid arthritis: Potential utility of power doppler sonography in clinical practice. |
| Q92464619 | Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry |
| Q47202397 | Radiographic progression in weight-bearing joints of patients with rheumatoid arthritis after TNF-blocking therapies |
| Q35637041 | Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset |
| Q37601987 | Ramsay hunt syndrome in a patient with rheumatoid arthritis after treatment with infliximab |
| Q35098842 | Randomised double-blind trial of combination antibiotic therapy in rheumatoid arthritis |
| Q34850808 | Randomized controlled trial of a nurse-led rheumatology clinic for monitoring biological therapy. |
| Q46929682 | Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density |
| Q44750988 | Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis |
| Q37020532 | Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. |
| Q37616417 | Rational/antiemotional behaviors in interpersonal relationships and the functional prognosis of patients with rheumatoid arthritis: a Japanese multicenter, longitudinal study |
| Q33234139 | Rationale and design of The Delphi Trial--I(RCT)2: international randomized clinical trial of rheumatoid craniocervical treatment, an intervention-prognostic trial comparing 'early' surgery with conservative treatment [ISRCTN65076841] |
| Q51748891 | Real-World Treatment Patterns for Golimumab and Concomitant Medications in Japanese Rheumatoid Arthritis Patients. |
| Q53307697 | Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry. |
| Q37501529 | Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study |
| Q88686840 | Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleis |
| Q36485737 | Recent paradigm shifts in the diagnosis and treatment of rheumatoid arthritis |
| Q36670140 | Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry. |
| Q38991582 | Receptor activator of nuclear factor kappa B ligand serum and synovial fluid level. A comparative study between rheumatoid arthritis and osteoarthritis |
| Q33592037 | Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis. |
| Q36013923 | Redefining overweight and obesity in rheumatoid arthritis patients. |
| Q46847821 | Redox-mediated angiogenesis in the hypoxic joint of inflammatory arthritis |
| Q42276429 | Reduced numbers of regulatory B cells are negatively correlated with disease activity in patients with new-onset rheumatoid arthritis |
| Q33611351 | Reduced trabecular bone mineral density and cortical thickness accompanied by increased outer bone circumference in metacarpal bone of rheumatoid arthritis patients: a cross-sectional study |
| Q45929457 | Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. |
| Q85941935 | Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis-results from the TOMORROW study |
| Q36732112 | Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register |
| Q33941664 | Regulatory B cells are inversely associated with disease activity in rheumatoid arthritis |
| Q53066864 | Regulatory T cells in rheumatoid arthritis showed increased plasticity toward Th17 but retained suppressive function in peripheral blood. |
| Q64113326 | Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature |
| Q52869895 | Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. |
| Q51082282 | Relation between bone mineral density and IL-17 serum levels in Serbian patients with early Rheumatoid arthritis. |
| Q46620150 | Relation of rheumatoid factor and anti-cyclic citrullinated peptide antibody with disease activity in rheumatoid arthritis: cross-sectional study |
| Q58134820 | Relationship Between Leptin and Neopterin Levels and Disease Activation Parameters in Patients With Rheumatoid Arthritis |
| Q55513283 | Relationship between beliefs about medicines, adherence to treatment, and disease activity in patients with rheumatoid arthritis under subcutaneous anti-TNFα therapy. |
| Q50317491 | Relationship between disease activity and hearing impairment in patients with rheumatoid arthritis compared with controls. |
| Q37504544 | Relationship between handedness and joint involvement in rheumatoid arthritis |
| Q45354032 | Relationship between psoriatic arthritis and moderate-severe psoriasis: analysis of a series of 166 psoriatic arthritis patients selected from a hospital population. |
| Q50881501 | Relationship between pulse wave velocity and serum YKL-40 level in patients with early rheumatoid arthritis. |
| Q90447556 | Relationship between rheumatoid arthritis and locomotive syndrome: validation of the 25-question Geriatric Locomotive Function Scale in patients with rheumatoid arthritis |
| Q41497288 | Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. |
| Q80473589 | Relationship between serum levels of IL-18 and IgG1 in patients with primary Sjögren's syndrome, rheumatoid arthritis and healthy controls |
| Q28290930 | Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients |
| Q33915665 | Relationship between time-integrated disease activity estimated by DAS28-CRP and radiographic progression of anatomical damage in patients with early rheumatoid arthritis |
| Q50776302 | Relationship of osteoprotegerin to pulse wave velocity and carotid intima-media thickness in rheumatoid arthritis patients. |
| Q53540861 | Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. |
| Q51115906 | Relationships between body mass index, fat mass, muscle mass, and musculoskeletal pain in community residents. |
| Q42562298 | Relative responsiveness of physician/assessor-derived and patient-derived core set measures in rheumatoid arthritis trials. |
| Q89498874 | Reliability and Validity of the Turkish Version of the ABILHAND Questionnaire in Rheumatoid Arthritis Individuals, Based on Rasch Analysis |
| Q38900339 | Reliability of the rheumatoid arthritis articular damage score in Tunisian patients |
| Q42010442 | Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor |
| Q36392370 | Remission by composite scores in rheumatoid arthritis: are ankles and feet important? |
| Q37738105 | Remission in juvenile idiopathic arthritis: current facts |
| Q37691184 | Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs |
| Q90454101 | Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network |
| Q33260342 | Remission, a therapeutic goal in inflammatory arthropathies? Clinical data from adalimumab studies |
| Q48198050 | Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. |
| Q36189976 | Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort |
| Q53819679 | Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. |
| Q60212995 | Reply |
| Q90417661 | Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial |
| Q61633956 | Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study |
| Q35607665 | Resistance exercise reduces skeletal muscle cachexia and improves muscle function in rheumatoid arthritis |
| Q86313523 | Resistin in inflammatory and degenerative rheumatologic diseases. Relationship between resistin and rheumatoid arthritis disease progression |
| Q35760141 | Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum |
| Q48115866 | Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells |
| Q34027546 | Respiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study |
| Q39618633 | Respiratory symptoms in rheumatoid arthritis: relation to pulmonary abnormalities detected by high-resolution CT and pulmonary functional testing |
| Q50323773 | Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics. |
| Q40850003 | Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis |
| Q26782095 | Response to peripheral immune stimulation within the brain: magnetic resonance imaging perspective of treatment success |
| Q73521737 | Responsiveness of the self-assessed rheumatoid arthritis disease activity index to a flare of disease activity |
| Q35636768 | Responsiveness of the shoulder function assessment scale in patients with rheumatoid arthritis. |
| Q33912921 | Resting energy expenditure is not associated with disease activity in women with rheumatoid arthritis: cross-sectional study. |
| Q59577297 | Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment |
| Q48008568 | Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations |
| Q35555747 | Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis |
| Q43444262 | Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. |
| Q48323417 | Retinal vessel morphology in rheumatoid arthritis: Association with systemic inflammation, subclinical atherosclerosis, and cardiovascular risk |
| Q35569500 | Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis |
| Q38085279 | Review on the influence of protocol design on clinical outcomes in rheumatoid arthritis treated with rituximab |
| Q39144067 | Review: Extracellular Vesicles in Joint Inflammation. |
| Q33727015 | Rheumatic autoimmune diseases in women and midlife health |
| Q36310765 | Rheumatic disease among Oklahoma tribal populations: a cross-sectional study |
| Q28552801 | Rheumatoid Arthritis Disease Activity Is Determinant for ABCB1 and ABCG2 Drug-Efflux Transporters Function |
| Q37309669 | Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study |
| Q89965809 | Rheumatoid Arthritis Patients, Both Newly Diagnosed and Methotrexate Treated, Show More DNA Methylation Differences in CD4+ Memory Than in CD4+ Naïve T Cells |
| Q38847626 | Rheumatoid Arthritis Treatment after Methotrexate: Triple Therapy is more Durable than Etanercept |
| Q92702522 | Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs? |
| Q38403772 | Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased? |
| Q36001551 | Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative |
| Q87726283 | Rheumatoid arthritis |
| Q35758617 | Rheumatoid arthritis and periodontitis - inflammatory and infectious connections. Review of the literature |
| Q33637603 | Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice |
| Q39243131 | Rheumatoid arthritis during pregnancy and postnatal catch-up growth in the offspring |
| Q43930077 | Rheumatoid arthritis in Burkina Faso: clinical and serological profiles |
| Q26799803 | Rheumatoid arthritis in Latin America: the importance of an early diagnosis |
| Q42955977 | Rheumatoid arthritis in Lebanese patients: characteristics in a tertiary referral centre in Beirut city. |
| Q51729843 | Rheumatoid arthritis in the United Arab Emirates. |
| Q40015472 | Rheumatoid arthritis is still expensive in the new decade: a comparison between two early RA cohorts, diagnosed 1996-98 and 2006-09. |
| Q60592413 | Rheumatoid arthritis is sufficient to cause atheromatosis but not arterial stiffness or hypertrophy in the absence of classical cardiovascular risk factors |
| Q36839197 | Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy |
| Q36842389 | Rheumatoid arthritis treatment with TNF inhibitors and alternative procedures in case of its failure - results of the Polish survey in the context of EULAR recommendations |
| Q47817154 | Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries |
| Q30244019 | Rheumatoid arthritis. |
| Q44927864 | Rheumatoid arthritis: assessing disease activity and outcome |
| Q37120627 | Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists |
| Q37206912 | Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study |
| Q35596467 | Rheumatoid cachexia revisited: a metabolic co-morbidity in rheumatoid arthritis |
| Q83585898 | Rheumatoid cachexia, central obesity and malnutrition in patients with low-active rheumatoid arthritis: feasibility of anthropometry, Mini Nutritional Assessment and body composition techniques |
| Q33996117 | Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study |
| Q37358983 | Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate |
| Q35755442 | Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials |
| Q92442225 | Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis |
| Q51187397 | Risk factors associated with the occurrence of distal radius fractures in Japanese patients with rheumatoid arthritis: a prospective observational cohort study. |
| Q51325090 | Risk factors associated with the occurrence of hip fracture in Japanese patients with rheumatoid arthritis: a prospective observational cohort study. |
| Q50929858 | Risk factors associated with the occurrence of proximal humerus fractures in patients with rheumatoid arthritis: a custom strategy for preventing proximal humerus fractures. |
| Q43432276 | Risk factors for established vertebral fractures in Japanese patients with rheumatoid arthritis: Results from a large prospective observational cohort study |
| Q41617609 | Risk factors for the rapid increase in risk of acute coronary events in patients with new-onset rheumatoid arthritis: a nested case-control study |
| Q33731716 | Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis |
| Q92771595 | Risk of major adverse cardiovascular events among patients with rheumatoid arthritis after initial CT-based diagnosis and treatment |
| Q35200349 | Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register |
| Q36679750 | Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register |
| Q35605468 | Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. |
| Q24186568 | Rituximab for rheumatoid arthritis |
| Q24242554 | Rituximab for rheumatoid arthritis |
| Q36108479 | Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure |
| Q36382724 | Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. |
| Q44493225 | Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients. |
| Q37350960 | Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response |
| Q38503363 | Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium |
| Q35605438 | Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study |
| Q46158731 | Role of NOD1 polymorphism in susceptibility and clinical progression of rheumatoid arthritis |
| Q46897841 | Role of cytolytic impairment of natural killer and natural killer T-cell populations in rheumatoid arthritis |
| Q46350423 | Role of hydrotherapy in the amelioration of oxidant-antioxidant status in rheumatoid arthritis patients. |
| Q21131938 | Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients |
| Q44021311 | Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study. |
| Q51043783 | Rosuvastatin-Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study. |
| Q35755789 | Routine Assessment of Patient Index Data (RAPID3) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Scores Yield Similar Information in 85 Korean Patients With Ankylosing Spondylitis Seen in Usual Clinical Care |
| Q38191587 | S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis |
| Q45055039 | SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients |
| Q42199862 | SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients |
| Q28554987 | STAT6 and STAT1 Pathway Activation in Circulating Lymphocytes and Monocytes as Predictor of Treatment Response in Rheumatoid Arthritis |
| Q35026454 | Safety and clinical efficacy of golimumab in the treatment of arthritides |
| Q34076916 | Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study |
| Q38817268 | Safety and effectiveness of etanercept for treatment of juvenile idiopathic arthritis: Results from a postmarketing surveillance |
| Q39430200 | Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. |
| Q37412858 | Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study |
| Q37326017 | Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial |
| Q42628958 | Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial |
| Q40336301 | Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection |
| Q40857120 | Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective post-marketing surveillance. |
| Q35674568 | Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East |
| Q47755721 | Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis. |
| Q38374478 | Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. |
| Q92615849 | Salivary interleukin 6, interleukin 8, interleukin 17A, and tumour necrosis factor α levels in patients with periodontitis and rheumatoid arthritis |
| Q38062332 | Same-day or historical ESR for disease activity score measurement: does it matter? |
| Q60922792 | Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors |
| Q92562240 | Sarcopenia in osteoarthritis and rheumatoid arthritis: The association with self-reported fatigue, physical function and obesity |
| Q34465354 | Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study |
| Q39176539 | Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors |
| Q35749767 | Scaffold protein Disc large homolog 1 is required for T-cell receptor-induced activation of regulatory T-cell function |
| Q49588168 | Scores versus clinical profiles in therapeutic decisions: a positive example from the Italian Medicines Agency (AIFA) decisions in the field of osteoporosis |
| Q91641942 | Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients |
| Q36818604 | Seasonal disease activity and serum vitamin D levels in rheumatoid arthritis, ankylosing spondylitis and osteoarthritis. |
| Q48219239 | Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study. |
| Q40606429 | Secular Changes in Clinical Features at Presentation of Rheumatoid Arthritis: Increase in Comorbidity But Improved Inflammatory States |
| Q34601386 | Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism |
| Q50213482 | Self-efficacy and pain acceptance as mediators of the relationship between pain and performance of valued life activities in women and men with rheumatoid arthritis |
| Q37275562 | Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications. |
| Q37597083 | Semaphorin 7A as a potential immune regulator and promising therapeutic target in rheumatoid arthritis |
| Q47812160 | Sense of coherence and self-sacrificing defense style as predictors of psychological distress and quality of life in rheumatoid arthritis: a 5-year prospective study |
| Q58051966 | Sensorineural Hearing Impairment and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients Without Traditional Cardiovascular Risk Factors |
| Q47883430 | Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. |
| Q42340113 | Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab |
| Q35840769 | Seropositivity is associated with insulin resistance in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR): an observational study |
| Q98772508 | Serum C-Reactive Protein/Albumin Ratio in Rheumatoid Arthritis and its Relationship With Disease Activity, Physical Function, and Quality of Life |
| Q36188496 | Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission |
| Q48247861 | Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors. |
| Q36415868 | Serum Markers in Rheumatoid Arthritis: A Longitudinal Study of Patients Undergoing Infliximab Treatment |
| Q94596628 | Serum Neuropeptide Y Levels Are Associated with TNF-α Levels and Disease Activity in Rheumatoid Arthritis |
| Q57157968 | Serum P-glycoprotein level: a potential biomarker of DMARD failure in patients with rheumatoid arthritis |
| Q89498868 | Serum Pyridinoline is Associated With Radiographic Joint Erosions in Rheumatoid Arthritis |
| Q35931065 | Serum Vitamin D and Pyridinoline Cross-Linked Carboxyterminal Telopeptide of Type I Collagen in Patients with Ankylosing Spondylitis |
| Q83774566 | Serum adenosine deaminase may predict disease activity in rheumatoid arthritis |
| Q34697924 | Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis |
| Q50950173 | Serum and synovial cartilage oligomeric matrix protein levels in early and established rheumatoid arthritis. |
| Q84847776 | Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA |
| Q83081026 | Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis |
| Q36067062 | Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. |
| Q82300321 | Serum chemokines in patients with rheumatoid arthritis treated with etanercept |
| Q92310651 | Serum hepcidin level and rheumatoid arthritis disease activity |
| Q36304059 | Serum leptin and serum leptin/serum leptin receptor ratio imbalance in obese rheumatoid arthritis patients positive for anti-cyclic citrullinated peptide antibodies |
| Q38425628 | Serum levels of IL-17, IL-4, and INFγ in Serbian patients with early rheumatoid arthritis |
| Q58051983 | Serum levels of anticyclic citrullinated peptide antibodies, interleukin-6, tumor necrosis factor-α, and C-reactive protein are associated with increased carotid intima-media thickness: a cross-sectional analysis of a cohort of rheumatoid arthritis |
| Q43945835 | Serum levels of calreticulin in correlation with disease activity in patients with rheumatoid arthritis |
| Q84183116 | Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course |
| Q83114757 | Serum levels of soluble CD26 and CD30 and their clinical significance in patients with rheumatoid arthritis |
| Q37445090 | Serum levels of vasoactive intestinal peptide as a prognostic marker in early arthritis |
| Q46632820 | Serum miR-210 and miR-155 expression levels as novel biomarkers for rheumatoid arthritis diagnosis. |
| Q36326701 | Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis |
| Q80142308 | Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers |
| Q86478450 | Serum progranulin irrelated with Breg cell levels, but elevated in RA patients, reflecting high disease activity |
| Q37154897 | Serum proteome analysis in patients with rheumatoid arthritis receiving therapy with tocilizumab: an anti-interleukin-6 receptor antibody |
| Q47831726 | Serum serotonin levels and bone in rheumatoid arthritis patients. |
| Q51627957 | Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study. |
| Q34027422 | Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity |
| Q51133170 | Severe low back pain in patients with rheumatoid arthritis is associated with Disease Activity Score but not with radiological findings on plain X-rays. |
| Q36194217 | Severity and Diurnal Improvement of Morning Stiffness Independently Associate with Tenosynovitis in Patients with Rheumatoid Arthritis. |
| Q36584051 | Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis -- results from the DANBIO registry |
| Q33424033 | Sex differences in rheumatoid arthritis: more than meets the eye.. |
| Q56890888 | Sex-based differences in association between circulating T cell subsets and disease activity in untreated early rheumatoid arthritis patients |
| Q35638333 | Sex: a major predictor of remission in early rheumatoid arthritis? |
| Q48455659 | Sexual functioning of people with rheumatoid arthritis: a multicenter study |
| Q48060466 | Shared care or nurse consultations as an alternative to rheumatologist follow-up for rheumatoid arthritis (RA) outpatients with stable low disease-activity RA: cost-effectiveness based on a 2-year randomized trial |
| Q29030405 | Shared care or nursing consultations as an alternative to rheumatologist follow-up for rheumatoid arthritis outpatients with low disease activity—patient outcomes from a 2-year, randomised controlled trial |
| Q51752628 | Short-term efficacy and safety of leflunomide in the treatment of active rheumatoid arthritis in everyday clinical use : open-label, prospective study. |
| Q35959088 | Sialyltransferase and Neuraminidase Levels/Ratios and Sialic Acid Levels in Peripheral Blood B Cells Correlate with Measures of Disease Activity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Pilot Study |
| Q48149385 | Siglec-9 is upregulated in rheumatoid arthritis and suppresses collagen-induced arthritis through reciprocal regulation of Th17-/Treg-cell differentiation. |
| Q35257568 | Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis |
| Q36074856 | Significantly impaired shoulder function in the first years of rheumatoid arthritis: a controlled study. |
| Q40746106 | Signs of forefeet joint synovitis have a limited impact on patient's perception of rheumatoid arthritis disease activity and acute-phase reactants |
| Q33576876 | Silent progression in patients with rheumatoid arthritis: is DAS28 remission an insufficient goal in RA? Results from the German Remission-plus cohort |
| Q37053620 | Silibinin Improves the Effects of Methotrexate in Patients with Active Rheumatoid Arthritis: Pilot Clinical Study. |
| Q64260049 | Similar alteration for mental and physical aspects in health-related quality of life over 5 to 8 years in 1347 patients with early arthritis and early inflammatory back pain |
| Q59313325 | Simvastatin inhibits cytokines in a dose response in patients with rheumatoid arthritis |
| Q57491401 | Sinomenine Inhibits the Progression of Rheumatoid Arthritis by Regulating the Secretion of Inflammatory Cytokines and Monocyte/Macrophage Subsets |
| Q48109783 | Six and 12 months' effects of individual joint protection education in people with rheumatoid arthritis: a randomized controlled trial |
| Q48332071 | Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides. |
| Q90038004 | Sleep disorders in patients with psoriatic arthritis and psoriasis |
| Q47999054 | Sleep quality and correlates of poor sleep in patients with rheumatoid arthritis |
| Q37417145 | Sleep quality in Chinese patients with rheumatoid arthritis: contributing factors and effects on health-related quality of life. |
| Q48018975 | Sleep quality in patients with psoriatic arthritis |
| Q40089620 | Sleep quality in patients with systemic sclerosis: relationship between the clinical variables, depressive symptoms, functional status, and the quality of life |
| Q35626270 | Sleep quality in rheumatoid arthritis, and its association with disease activity in a Korean population |
| Q37438264 | Sleep quality in rheumatoid arthritis: relationship between the disease severity, depression, functional status and the quality of life |
| Q35959559 | Smelling the Diagnosis: The Electronic Nose as Diagnostic Tool in Inflammatory Arthritis. A Case-Reference Study |
| Q94348338 | Smoking cessation intervention for reducing disease activity in chronic autoimmune inflammatory joint diseases |
| Q37689716 | Smoking in combination with antibodies to cyclic citrullinated peptides is associated with persistently high levels of survivin in early rheumatoid arthritis: a prospective cohort study |
| Q37026956 | Socioeconomic determinants of disability and depression in patients with rheumatoid arthritis |
| Q28475485 | Soluble Biomarkers of Cartilage and Bone Metabolism in Early Proof of Concept Trials in Psoriatic Arthritis: Effects of Adalimumab Versus Placebo |
| Q35092966 | Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis |
| Q42475068 | Soluble triggering receptor expressed on myeloid cells-1 is a biomarker of anti-CCP-positive, early rheumatoid arthritis |
| Q49068391 | Somatization is associated with physical health-related quality of life independent of anxiety and depression in cancer, glaucoma and rheumatological disorders |
| Q73880405 | Sonographic evaluation of the elbow in rheumatoid arthritis: a classification of joint destruction |
| Q45230346 | Sonographic measurements of low-echoic synovial area in the dorsal aspect of metatarsophalangeal joints in healthy subjects |
| Q48106857 | Spa therapy adjunct to pharmacotherapy is beneficial in rheumatoid arthritis: a crossover randomized controlled trial. |
| Q34956331 | Spiritual healing in the treatment of rheumatoid arthritis: an exploratory single centre, parallel-group, double-blind, three-arm, randomised, sham-controlled trial. |
| Q39694655 | Stability of clinical outcome measures in rheumatoid arthritis patients with stable disease defined on the basis of the EULAR response criteria |
| Q50888240 | Stages of change, barriers, benefits, and preferences for exercise in RA patients: a cross-sectional study. |
| Q46167690 | Standardized grip strength as an outcome measure in early rheumatoid arthritis. |
| Q54105644 | Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis. |
| Q38409321 | Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid Arthri |
| Q43617091 | Sternoclavicular joint involvement in rheumatoid arthritis: clinical and ultrasound findings of a neglected joint |
| Q48241174 | Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial |
| Q44138172 | Stressors and rheumatoid arthritis: changes in stressors with advances in therapeutic agents |
| Q79080037 | Stress–vulnerability factors as long-term predictors of disease activity in early rheumatoid arthritis |
| Q36116344 | Structural and morphological changes in the eyes of arterial hypertensive patients with and without anti-CCP-positive rheumatoid arthritis |
| Q53082476 | Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis. |
| Q50701578 | Structural deterioration of finger joints with ultrasonographic synovitis in rheumatoid arthritis patients with clinical low disease activity. |
| Q34590834 | Subclinical atherosclerosis in patients with rheumatoid arthritis by utilizing carotid intima-media thickness as a surrogate marker. |
| Q54571723 | Subclinical reduced G6PD activity in rheumatoid arthritis and Sjögren's Syndrome patients: relation to clinical characteristics, disease activity and metabolic syndrome. |
| Q35590496 | Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. |
| Q24187565 | Subcutaneous or intramuscular methotrexate for rheumatoid arthritis |
| Q34036038 | Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience |
| Q50690412 | Subendocardial viability ratio in patients with rheumatoid arthritis: comparison with healthy controls and identification of prognostic factors. |
| Q58720531 | Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health |
| Q47633961 | Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab |
| Q90250659 | Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study |
| Q33651708 | Survival dimensionality reduction (SDR): development and clinical application of an innovative approach to detect epistasis in presence of right-censored data |
| Q41687151 | Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial |
| Q34803197 | Sustainability of rituximab therapy in different treatment strategies: results of a 3-year followup of a German biologics register |
| Q45078242 | Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort |
| Q58220963 | Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS |
| Q44754660 | Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis |
| Q90614968 | Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study |
| Q36245761 | Sustained rheumatoid arthritis remission is uncommon in clinical practice |
| Q64922356 | Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, doubl |
| Q50034734 | Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: 52-Week Phase 3 Randomized Study Results |
| Q38787053 | Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial |
| Q36205262 | Symmetric Dimethylarginine Is Not Associated with Cumulative Inflammatory Load or Classical Cardiovascular Risk Factors in Rheumatoid Arthritis: A 6-Year Follow-Up Study |
| Q37455123 | Symmetric dimethyl arginine and N-acetyl-β-D-glucosaminidase lysozimuria of proximal renal tubules as a target for nephrotoxicity in patients with rheumatoid arthritis treated with disease modifying antirheumatic drugs |
| Q53583233 | Symmetric dimethylarginine (SDMA) serum levels in rheumatoid arthritis: correlations with insulin resistance and disease activity scores. |
| Q33648606 | Symptom complexes at the earliest phases of rheumatoid arthritis: a synthesis of the qualitative literature. |
| Q50523565 | Synovial Immunophenotype and Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiologic Prognosis. |
| Q39904758 | Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade. |
| Q36930634 | Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response |
| Q46212960 | Synovial/serum leptin ratio in rheumatoid arthritis: the association with activity and erosion |
| Q38592344 | Synthetic disease-modifying antirheumatic drug prescribing variability in rheumatoid arthritis: a multilevel analysis of a cross-sectional national study. |
| Q33240856 | Systematic review of measures and their concepts used in published studies focusing on the treatment of acute inflammatory arthritis |
| Q36294542 | Systematic review of the methodological quality of controlled trials evaluating Chinese herbal medicine in patients with rheumatoid arthritis |
| Q47163408 | Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomen |
| Q38864249 | Systemic and localized infection by Candida species in patients with rheumatic diseases receiving anti-TNF therapy |
| Q34550743 | Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis |
| Q37144029 | T helper 17 and T helper 1 cells are increased but regulatory T cells are decreased in subchondral bone marrow microenvironment of patients with rheumatoid arthritis |
| Q35924790 | TCRzetadim lymphocytes define populations of circulating effector cells that migrate to inflamed tissues |
| Q39272815 | TIM-1 rs41297579 G>A (-1454) and TIM-4 rs7700944 gene polymorphisms as possible risk factor for rheumatoid arthritis: relation to activity and severity. |
| Q35849817 | TNF downmodulates the function of human CD4+CD25hi T-regulatory cells |
| Q31017424 | Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry |
| Q30249836 | Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions |
| Q50074419 | Targeting of circulating Th17 cells by β-D-mannuronic acid (M2000) as a novel medication in patients with rheumatoid arthritis. |
| Q44935657 | Tc-99 m diethylenetriamine-pentaacetic acid (DTPA): is it reliable for assessment of methotrexate-induced cumulative effect on renal filtration in rheumatoid arthritis patients? |
| Q83844887 | Tc-99m sestamibi lower extremity muscle scan, is it a useful screening tool for assessment of preclinical atherosclerosis in rheumatoid arthritis patients? |
| Q43442778 | Team-based rehabilitation improves long-term aerobic capacity and health-related quality of life in patients with chronic inflammatory arthritis |
| Q57456657 | Telomere dysfunction-related serological markers and oxidative stress markers in rheumatoid arthritis patients: correlation with diseases activity |
| Q36275585 | Temperature changes in rheumatoid hand treated with nitrogen vapors and cold air. |
| Q48226009 | Temporal associations between the different domains of rheumatoid arthritis disease activity and the onset of patient-reported depressive symptoms |
| Q36950687 | Temporal effect of depressive symptoms on the longitudinal evolution of rheumatoid arthritis disease activity |
| Q35986249 | Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway |
| Q57171084 | Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway |
| Q41307391 | Tespa1 is associated with susceptibility but not severity of rheumatoid arthritis in the Zhejiang Han population in China. |
| Q45223225 | Test-retest reliability of the disease activity score 28 CRP (DAS28-CRP), the simplified disease activity index (SDAI) and the clinical disease activity index (CDAI) in rheumatoid arthritis when based on patient self-assessment of tender and swollen |
| Q50467012 | Testing the role of vitamin D in response to antitumour necrosis factor α therapy in a UK cohort: a Mendelian randomisation approach. |
| Q36714071 | Tetrahydrobiopterin Supplementation Improves Endothelial Function But Does Not Alter Aortic Stiffness in Patients With Rheumatoid Arthritis |
| Q35336802 | The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug |
| Q41320881 | The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis. |
| Q40573679 | The -2518 A/G polymorphism in the monocyte chemoattractant protein 1 gene (MCP-1) is associated with an increased risk of rheumatoid arthritis in Argentine patients |
| Q44355131 | The -383A>C TNFRI polymorphism is associated with soluble levels and clinical activity in rheumatoid arthritis. |
| Q37374964 | The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial |
| Q53244572 | The Association Between Neutrophil/Lymphocyte Ratio and Disease Activity in Rheumatoid Arthritis and Ankylosing Spondylitis. |
| Q36572818 | The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab |
| Q92493110 | The Endogenous Plasma Small RNAome of Rheumatoid Arthritis |
| Q90479678 | The Expansion of Myeloid-Derived Suppressor Cells Is Associated with Joint Inflammation in Rheumatic Patients with Arthritis |
| Q92224133 | The Impact of Exercise, Lifestyle, and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study |
| Q26827463 | The Link Between Periodontitis and Rheumatoid Arthritis: A Periodontist's Perspective |
| Q35841820 | The Minor Allele of rs7574865 in the STAT4 Gene Is Associated with Increased mRNA and Protein Expression |
| Q58769263 | The Natural Agonist of Estrogen Receptor β Silibinin Plays an Immunosuppressive Role Representing a Potential Therapeutic Tool in Rheumatoid Arthritis |
| Q36392280 | The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden |
| Q37169353 | The Relationship Between Function and Disease Activity as Measured by the HAQ and DAS28 Varies Over Time and by Rheumatoid Factor Status in Early Inflammatory Arthritis (EIA). Results from the CATCH Cohort |
| Q37609311 | The Short Form Score for the Assessment and Quantification of Chronic Rheumatic Affections of the Hands in Daily Clinical Routines-Its Sensitivity to Change and Preliminary Patient Relevant Variation Values: A Pilot Study |
| Q34399280 | The TT genotype of the STAT4 rs7574865 polymorphism is associated with high disease activity and disability in patients with early arthritis |
| Q45928777 | The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. |
| Q40061950 | The Temporal Relationship between Arterial Stiffening and Blood Pressure Is Modified by Methotrexate Treatment in Patients with Rheumatoid Arthritis |
| Q39994707 | The Use of Avoidance, Adjustment, Interaction and Acceptance Strategies to Handle Participation Restrictions Among Swedish Men with Early Rheumatoid Arthritis |
| Q98289420 | The Use of Oral Analgesics and Pain Self-Efficacy Are Independent Predictors of the Quality of Life of Individuals with Rheumatoid Arthritis |
| Q58801819 | The Utility and Limitations of CRP, ESR and DAS28-CRP in Appraising Disease Activity in Rheumatoid Arthritis |
| Q36317414 | The abnormal expression of CCR4 and CCR6 on Tregs in rheumatoid arthritis |
| Q41282388 | The added value of musculoskeletal ultrasound to clinical evaluation in the treatment decision of rheumatoid arthritis outpatients: physician experience matters. |
| Q30914777 | The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials |
| Q37621159 | The adjuvant use of calcium fructoborate and borax with etanercept in patients with rheumatoid arthritis: Pilot study. |
| Q64104400 | The agreement between ultrasound-determined joint inflammation and clinical signs in patients with rheumatoid arthritis |
| Q58998900 | The anti-CD20 antibody rituximab reduces the Th17 cell response |
| Q48265755 | The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. |
| Q90434053 | The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis |
| Q36790405 | The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study |
| Q34980274 | The association between functional and morphological assessments of endothelial function in patients with rheumatoid arthritis: a cross-sectional study |
| Q33938590 | The association between microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional study. |
| Q35135726 | The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis |
| Q51050640 | The beneficial effect of total glucosides of paeony on psoriatic arthritis links to circulating Tregs and Th1 cell function. |
| Q73927216 | The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care |
| Q46457918 | The changes in serum chemokines following leflunomide therapy in patients with rheumatoid arthritis. |
| Q91700233 | The clinical value of hematological markers in rheumatoid arthritis patients treated with tocilizumab |
| Q35048356 | The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor |
| Q53503464 | The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. |
| Q64061122 | The comparative responsiveness of Hospital Universitario Princesa Index and other composite indices for assessing rheumatoid arthritis activity |
| Q37387224 | The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis |
| Q40586509 | The contribution of four immunogenetic markers for predicting persistent activity in patients with recent-onset rheumatoid arthritis or undifferentiated arthritis |
| Q41227639 | The correlation between ferritin level and acute phase parameters in rheumatoid arthritis and systemic lupus erythematosus |
| Q34474506 | The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients |
| Q85793696 | The detection of calcium pyrophosphate crystals in the synovial fluid of patients with rheumatoid arthritis using the cytospin technique: prevalence and clinical correlation |
| Q50463638 | The differentiation of anaemia in rheumatoid arthritis: parameters of iron-deficiency in an Indian rheumatoid arthritis population. |
| Q34558300 | The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases. |
| Q79319452 | The disease process and utilization of health services in rheumatoid arthritis: the relative contributions of various markers of disease severity in explaining consumption patterns |
| Q43137485 | The effect of alcohol on radiographic progression in rheumatoid arthritis |
| Q47133987 | The effect of an intensive smoking cessation intervention on disease activity in patients with rheumatoid arthritis: study protocol for a randomised controlled trial |
| Q46088038 | The effect of anti-TNF-α vs. DMARDs on fatigue in rheumatoid arthritis patients |
| Q35557429 | The effect of disease activity on body composition and resting energy expenditure in patients with rheumatoid arthritis |
| Q35636615 | The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis |
| Q37177587 | The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis |
| Q51463578 | The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis. |
| Q44593198 | The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis |
| Q57603257 | The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients |
| Q34626882 | The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy |
| Q40900237 | The effects of high intensity interval training in women with rheumatic disease: a pilot study |
| Q51294012 | The effects of periodontal therapy on gingival crevicular fluid matrix metalloproteinase-8, interleukin-6 and prostaglandin E2 levels in patients with rheumatoid arthritis. |
| Q46165734 | The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection |
| Q85172553 | The effects of strength and endurance training in patients with rheumatoid arthritis |
| Q47620622 | The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab |
| Q40772658 | The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, d |
| Q36204163 | The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice |
| Q55000909 | The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial. |
| Q47667591 | The evaluation of sleep quality and response to anti-tumor necrosis factor α therapy in rheumatoid arthritis patients |
| Q52942759 | The exaggerated inflammatory response in Behçet's syndrome: identification of dysfunctional post-transcriptional regulation of the IFN-γ/CXCL10 IP-10 pathway. |
| Q45749970 | The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure |
| Q46081724 | The good EULAR response at the first year is strongly predictive of clinical remission in rheumatoid arthritis: results from the TARAC cohort. |
| Q33467606 | The impact of rheumatoid foot on disability in Colombian patients with rheumatoid arthritis. |
| Q36064093 | The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. |
| Q50916277 | The influence of patient perceptions of disease on medication intensification in daily practice. |
| Q45187063 | The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study |
| Q36245889 | The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients |
| Q86741114 | The limited effects of anti-tumor necrosis factor blockade on bone health in patients with rheumatoid arthritis under the use of glucocorticoid |
| Q81256806 | The long-term effect of anti TNF-alpha treatment on temporomandibular joints, oral mucosa, and salivary flow in patients with active rheumatoid arthritis: a pilot study |
| Q74309604 | The negative effect of decreasing the level of activity in coping with pain in rheumatoid arthritis: an increase in psychological distress and disease impact |
| Q34333827 | The neutrophil protein S100A12 is associated with a comprehensive ultrasonographic synovitis score in a longitudinal study of patients with rheumatoid arthritis treated with adalimumab |
| Q35942685 | The observation of humoral responses after influenza vaccination in patients with rheumatoid arthritis treated with Japanese oriental (kampo) medicine: an observational study |
| Q74552419 | The original "DAS" and the "DAS28" are not interchangeable: comment on the articles by Prevoo et al |
| Q80537897 | The patient-based outcome of upper-extremity surgeries using the DASH questionnaire and the effect of disease activity of the patients with rheumatoid arthritis |
| Q81933479 | The pattern and clinical manifestations of rheumatoid arthritis in Sarawak General Hospital |
| Q37691038 | The phenotype and genotype of rheumatoid arthritis in the Democratic Republic of Congo. |
| Q33731299 | The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort |
| Q91943789 | The prevalence and types of discordance between physician perception and objective data from standardized measures of rheumatoid arthritis disease activity in real-world clinical practice in the US |
| Q44793969 | The prevalence of vertebral fracture on vertebral fracture assessment imaging in a large cohort of patients with rheumatoid arthritis |
| Q45334293 | The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion |
| Q35557805 | The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial |
| Q81446240 | The relation of hand functions with radiological damage and disease activity in rheumatoid arthritis |
| Q34073425 | The relationship between change in subjective outcome and change in disease: a potential paradox |
| Q45910248 | The relationship between depressive symptoms, illness perceptions and quality of life in ankylosing spondylitis in comparison to rheumatoid arthritis. |
| Q84355413 | The relationship between disease activity and depression in patients with Behcet disease and rheumatoid arthritis |
| Q56332492 | The relationship between oral contraceptive use and functional outcome in women with recent-onset inflammatory polyarthritis: Results from the Norfolk Arthritis Register |
| Q35893575 | The risk factors for nosocomial infection in chinese patients with active rheumatoid arthritis in shanghai |
| Q40064452 | The role of dietary sodium intake on the modulation of T helper 17 cells and regulatory T cells in patients with rheumatoid arthritis and systemic lupus erythematosus. |
| Q59075060 | The role of disease activity score 28 in the evaluation of articular involvement in systemic lupus erythematosus |
| Q34272487 | The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study |
| Q36907676 | The role of inflammation, the autonomic nervous system and classical cardiovascular disease risk factors on subendocardial viability ratio in patients with RA: a cross-sectional and longitudinal study. |
| Q39341401 | The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry. |
| Q50074376 | The role of microalbuminuria as a predictor of subclinical cardiovascular events in rheumatoid arthritis patients and its relation to disease activity. |
| Q36503913 | The role of sleep problems in central pain processing in rheumatoid arthritis |
| Q58546118 | The rs878081 polymorphism of AIRE gene increases the risk of rheumatoid arthritis in a Chinese Han population: a case-control study |
| Q34713116 | The shared crosstalk of multiple pathways involved in the inflammation between rheumatoid arthritis and coronary artery disease based on a digital gene expression profile |
| Q37196596 | The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis |
| Q35840842 | The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab |
| Q59503659 | The subjective components of the Disease Activity Score 28-joints (DAS28) in rheumatoid arthritis patients and coexisting fibromyalgia |
| Q45249079 | The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin |
| Q37562571 | The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study |
| Q36916918 | The use of TNF-alpha blocking agents in rheumatoid arthritis: an update |
| Q30576366 | The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis |
| Q91601739 | The use of missing values in proteomic data-independent acquisition mass spectrometry to enable disease activity discrimination |
| Q33554356 | The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project |
| Q35557873 | The usefulness of magnetic resonance imaging of the hand and wrist in very early rheumatoid arthritis |
| Q33317043 | The utility of clinical decision tools for diagnosing osteoporosis in postmenopausal women with rheumatoid arthritis |
| Q34897125 | The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28 |
| Q83293579 | The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28 |
| Q36458132 | The world of biologics. |
| Q61946761 | The −590 IL-4 promoter polymorphism in patients with rheumatoid arthritis |
| Q58052205 | The −844 G/A PAI-1 polymorphism is associated with mRNA expression in rheumatoid arthritis |
| Q35923452 | Therapeutic antioxidant and anti-inflammatory effects of laser acupuncture on patients with rheumatoid arthritis |
| Q35636828 | Thermal signature analysis as a novel method for evaluating inflammatory arthritis activity. |
| Q87650612 | Three months of moderate-intensity exercise reduced plasma 3-nitrotyrosine in rheumatoid arthritis patients |
| Q47807214 | Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort |
| Q36837763 | Tibialis posterior tenosynovitis and associated pes plano valgus in rheumatoid arthritis: electromyography, multisegment foot kinematics, and ultrasound features. |
| Q36969898 | Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility |
| Q46988765 | Tight control of rheumatoid arthritis in a resource-constrained setting: a randomized controlled study comparing the clinical disease activity index and simplified disease activity index. |
| Q43854069 | Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy |
| Q40166955 | Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients. |
| Q58086499 | Time to include fine specificity ACPAs in the routine diagnosis and management of rheumatoid arthritis? |
| Q45790066 | Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. |
| Q53021496 | Tissue Doppler imaging in the evaluation of the left and right ventricular diastolic functions in rheumatoid arthritis. |
| Q51117846 | Titer-Dependent Effect of Anti-Citrullinated Protein Antibodies On Systemic Bone Mass in Rheumatoid Arthritis Patients. |
| Q24234126 | Tocilizumab for rheumatoid arthritis |
| Q24239949 | Tocilizumab for rheumatoid arthritis |
| Q36234050 | Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. |
| Q50703895 | Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospe |
| Q44165611 | Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial |
| Q46671185 | Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis. |
| Q37310678 | Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis |
| Q45842857 | Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial |
| Q24198120 | Tofacitinib for rheumatoid arthritis |
| Q42696887 | Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study |
| Q36513512 | Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study |
| Q28077994 | Total glucosides of paeony for rheumatoid arthritis: a protocol for a systematic review |
| Q36185264 | Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update |
| Q47107467 | Trabecular bone score as a supplementary tool for the discrimination of osteoporotic fractures in postmenopausal women with rheumatoid arthritis |
| Q93127395 | Transcription factor Fra-1 targets arginase-1 to enhance macrophage-mediated inflammation in arthritis |
| Q37672124 | Transcription factor NFAT5 promotes macrophage survival in rheumatoid arthritis |
| Q80089102 | Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy |
| Q42247134 | Transcriptional profiling of leukocytes from rheumatoid arthritis patients before and after anti-tumor necrosis factor therapy: A comparison of anti-nuclear antibody positive and negative subsets |
| Q30472063 | Transforming growth factor β 869C/T and interleukin 6 -174G/C polymorphisms relate to the severity and progression of bone-erosive damage detected by ultrasound in rheumatoid arthritis |
| Q91283958 | Treat-to-target in rheumatoid arthritis - are we there yet? |
| Q38476881 | Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force |
| Q37954077 | Treating to target in rheumatoid arthritis: biologic therapies |
| Q35065233 | Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry. |
| Q88443607 | Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis |
| Q35249608 | Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? |
| Q39815843 | Treatment of rheumatoid arthritis (RA) in India-how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal. |
| Q30680371 | Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data |
| Q37688075 | Treatment of rheumatoid arthritis with marine and botanical oils: an 18-month, randomized, and double-blind trial |
| Q46376552 | Treatment of rheumatoid arthritis with methotrexate in Congolese patients. |
| Q50553120 | Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. |
| Q89845978 | Treatment strategies are more important than drugs in the management of rheumatoid arthritis |
| Q44293608 | Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis |
| Q38743924 | Tregs restrain dendritic cell autophagy to ameliorate autoimmunity. |
| Q35637543 | Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics. |
| Q37129582 | Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohort |
| Q34327988 | Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial |
| Q87111600 | Tryptase is a candidate autoantigen in rheumatoid arthritis |
| Q84070984 | Tryptophan degradation and neopterin levels in treated rheumatoid arthritis patients |
| Q58606775 | Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy |
| Q38616681 | Tumor Necrosis Factor (TNF) Bioactivity at the Site of an Acute Cell-Mediated Immune Response Is Preserved in Rheumatoid Arthritis Patients Responding to Anti-TNF Therapy |
| Q85118797 | Tumor Necrosis Factor-α Up-Regulates the Expression of β1,4-Galactosyltransferase-I in Human Fibroblast-like Synoviocytes |
| Q36984088 | Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort |
| Q59042159 | Tumor necrosis factor blocking therapy alters joint inflammation and hypoxia |
| Q58052232 | Tumor necrosis factor receptor 2 M196R polymorphism in rheumatoid arthritis and osteoarthritis: relationship with sTNFR2 levels and clinical features |
| Q56835543 | Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions |
| Q42137831 | Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission |
| Q41571651 | Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial |
| Q41622867 | Ultrasonographic abnormalities and inter-reader reliability in Danish patients with systemic lupus erythematosus - a comparison with clinical examination of wrist and metacarpophalangeal joints. |
| Q43978434 | Ultrasonography predicts achievement of Boolean remission after DAS28-based clinical remission of rheumatoid arthritis. |
| Q82522937 | Ultrasonography shows significant improvement in wrist and ankle tenosynovitis in rheumatoid arthritis patients treated with adalimumab |
| Q57115206 | Ultrasound Assessment of Changes in Nails in Psoriasis and Psoriatic Arthritis |
| Q54572137 | Ultrasound evaluation of the effects of leukocytapheresis on rheumatoid arthritis. |
| Q33920387 | Ultrasound in rheumatoid arthritis: volar versus dorsal synovitis evaluation and scoring |
| Q36633112 | Ultrasound of metacarpophalangeal joints is a sensitive and reliable endpoint for drug therapies in rheumatoid arthritis: results of a randomized, two-center placebo-controlled study. |
| Q42278858 | Ultrasound of the hand is sufficient to detect subclinical inflammation in rheumatoid arthritis remission: a post hoc longitudinal study |
| Q40676684 | Ultrasound-detected tenosynovitis independently associates with patient-reported flare in patients with rheumatoid arthritis in clinical remission: results from the observational study STARTER of the Italian Society for Rheumatology. |
| Q87107267 | Ultrasound7 versus ultrasound12 in monitoring the response to infliximab in patients with rheumatoid arthritis |
| Q51667223 | Underweight and obese states both associate with worse disease activity and physical function in patients with established rheumatoid arthritis. |
| Q36923331 | Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study. |
| Q92302942 | Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study |
| Q36246077 | Upregulation of tumor necrosis factor receptor-associated factor 6 correlated with synovitis severity in rheumatoid arthritis |
| Q37350911 | Uric acid is a strong independent predictor of renal dysfunction in patients with rheumatoid arthritis |
| Q36656401 | Urinary Albumin Excretion and Vascular Function in Rheumatoid Arthritis |
| Q37330396 | Urinary interleukin-6 as a predictor of radiographic progression in rheumatoid arthritis: A 3-year evaluation |
| Q36127459 | Urine metabolome profiling of immune-mediated inflammatory diseases |
| Q40282463 | Use and perceived relevance of health-related Internet sites and online contact with peers among young people with juvenile idiopathic arthritis |
| Q90471055 | Use of Auto-Injector for Methotrexate Subcutaneous Self-Injections: High Satisfaction Level and Good Compliance in SELF-I Study, a Randomized, Open-Label, Parallel Group Study |
| Q37572857 | Use of Bayesian multivariate meta-analysis to estimate the HAQ for mapping onto the EQ-5D questionnaire in rheumatoid arthritis. |
| Q51104578 | Use of Hydroxychloroquine Is Associated With Improved Lipid Profile in Rheumatoid Arthritis Patients. |
| Q92193157 | Use of a "critical difference" statistical criterion improves the predictive utility of the Health Assessment Questionnaire-Disability Index score in patients with rheumatoid arthritis |
| Q42240087 | Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series |
| Q48063743 | Use of bisphosphonate might be important to improve bone mineral density in patients with rheumatoid arthritis even under tight control: the TOMORROW study. |
| Q38775077 | Use of complementary and alternative medicines is associated with delay to initiation of disease-modifying anti-rheumatic drug therapy in early inflammatory arthritis. |
| Q84641073 | Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis |
| Q53459559 | Use of ultrasound-guided small joint biopsy to evaluate the histopathologic response to rheumatoid arthritis therapy: recommendations for application to clinical trials. |
| Q50456837 | Use of xinfeng capsule to treat abarticular pathologic changes in patients with rheumatoid arthritis. |
| Q36302285 | Usefulness of patients-reported outcomes in rheumatoid arthritis focus group |
| Q34208244 | Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis. |
| Q45780447 | Users' experience of physical activity monitoring technology in rheumatoid arthritis. |
| Q37209219 | Using actigraphy to measure sleep patterns in rheumatoid arthritis: a pilot study in patients taking night-time prednisone |
| Q48503586 | Using technology to support clinical care and research in rheumatoid arthritis |
| Q90461853 | Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis |
| Q37630349 | Using ultrasonography to facilitate best practice in diagnosis and management of RA. |
| Q36117792 | Utility of Select Plasma MicroRNA for Disease and Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis |
| Q35652911 | Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis |
| Q35630128 | Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis |
| Q43170863 | Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort |
| Q38646919 | Validation and internal consistency of the Swedish version of the Valued Life Activities scale |
| Q39381766 | Validation of FLARE-RA, a Self-Administered Tool to Detect Recent or Current Rheumatoid Arthritis Flare |
| Q43925747 | Validation of RAPID3 using a Japanese version of Multidimensional Health Assessment Questionnaire with Japanese rheumatoid arthritis patients: characteristics of RAPID3 compared to DAS28 and CDAI. |
| Q40826531 | Validation of a flow cytometry-based assay to assess C5aR receptor occupancy on neutrophils and monocytes for use in drug development |
| Q36428250 | Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity |
| Q53067521 | Validation of disease activity indices using the 28 joint counts in systemic sclerosis. |
| Q58112107 | Validation of methods for converting the original Disease Activity Score (DAS) to the DAS28 |
| Q33915344 | Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials |
| Q63101754 | Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e |
| Q35953509 | Validation of the ABILHAND questionnaire as a measure of manual ability in patients with rheumatoid arthritis |
| Q46366513 | Validation of the rheumatic disease comorbidity index |
| Q53820042 | Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. |
| Q60679260 | Validierung der deutschen Version der regionalen Schmerzskala zur Diagnose des Fibromyalgiesyndroms |
| Q41510568 | Validity and Agreement between the 28-Joint Disease Activity Score Based on C-Reactive Protein and Erythrocyte Sedimentation Rate in Patients with Rheumatoid Arthritis |
| Q90235697 | Validity and interpretability of the QuickDASH in the assessment of hand disability in rheumatoid arthritis |
| Q33457544 | Validity and measurement precision of the PROMIS physical function item bank and a content validity-driven 20-item short form in rheumatoid arthritis compared with traditional measures |
| Q48063372 | Validity and responsiveness of a self-administered foot evaluation questionnaire in rheumatoid arthritis |
| Q92063403 | Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis |
| Q31122982 | Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria |
| Q33749962 | Validity of the Nurses' health study physical activity questionnaire in estimating physical activity in adults with rheumatoid arthritis |
| Q48105582 | Variability in the frequency of rheumatology consultations in patients with rheumatoid arthritis in Spain |
| Q28545783 | Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis |
| Q45766371 | Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth? |
| Q35954706 | Vascular calcifications on hand radiographs in rheumatoid arthritis and associations with autoantibodies, cardiovascular risk factors and mortality |
| Q53085906 | Very early improvements in the wrist and hand assessed by power Doppler sonography predicting later favorable responses in tocilizumab-treated patients with rheumatoid arthritis. |
| Q42635006 | Very high levels of anti-citrullinated protein antibodies are associated with HLA-DRB1*15 non-shared epitope allele in patients with rheumatoid arthritis |
| Q43749611 | Visfatin and adiponectin as novel markers for evaluation of metabolic disturbance in recently diagnosed rheumatoid arthritis patients |
| Q44315334 | Vitamin D level: is it related to disease activity in inflammatory joint disease? |
| Q47606725 | Vitamin D receptor polymorphisms and expression profile in rheumatoid arthritis Brazilian patients. |
| Q86765414 | Vitamin D status in men with psoriatic arthritis: a case-control study |
| Q46284288 | Vitamin D status in rheumatoid arthritis patients: relation to clinical manifestations, disease activity, quality of life and fibromyalgia syndrome |
| Q87649267 | Vitamin D status of patients with early inflammatory arthritis |
| Q48089725 | Waist circumference based abdominal obesity may be helpful as a marker for unmet needs in patients with RA. |
| Q35463979 | We should not forget the foot: relations between signs and symptoms, damage, and function in rheumatoid arthritis |
| Q60910366 | Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study |
| Q37928529 | What do microRNAs mean for rheumatoid arthritis? |
| Q35954625 | What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. |
| Q37627856 | What predicts negative effects of rheumatoid arthritis? A follow-up two years after diagnosis |
| Q51607220 | What predicts obesity in patients with rheumatoid arthritis? An investigation of the interactions between lifestyle and inflammation. |
| Q48552102 | Which clinical variables have the most significant correlation with quality of life evaluated by SF-36 survey in Croatian cohort of patient with ankylosing spondylitis and psoriatic arthritis? |
| Q33566367 | Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? |
| Q45087624 | Who are the patients with early arthritis with worse than death scores on the EQ-5D? Results from the ESPOIR cohort |
| Q92325556 | Widespread pain and pain intensity in patients with early rheumatoid arthritis. A cross-sectional comparison between smokers and non-smokers |
| Q44629204 | Willingness to pay for improvement of physical function among rheumatoid arthritis patients as measured by Health Assessment Questionnaire |
| Q35842618 | Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters |
| Q37207061 | Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study |
| Q48913303 | Work ability: a new outcome measure in rheumatoid arthritis? |
| Q51770477 | Work disability is related to the presence of arthritis and not to a specific diagnosis. Results from a large early arthritis cohort in Argentina. |
| Q33540305 | Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study |
| Q36505055 | Work productivity in rheumatoid arthritis: relationship with clinical and radiological features |
| Q33990812 | Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. |
| Q47843244 | Xinfeng capsule for the treatment of rheumatoid arthritis patients with decreased pulmonary function--a randomized controlled clinical trial |
| Q82638877 | [Clinical outcome measures in hand- and finger joint osteoarthritis from the patient perspective] |
| Q80307453 | [Comorbidity in rheumatoid arthritis of early onset. Effects on outcome parameters] |
| Q90258576 | [Depressive symptoms in early rheumatoid arthritis : Within the rheumatism network ADAPTHERA] |
| Q80688848 | [Early rheumatoid arthritis] |
| Q79192816 | [Effectiveness and safety of adalimumab and etanercept for rheumatoid arthritis in a third-level hospital] |
| Q79802311 | [Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab] |
| Q83825059 | [Health-related quality of life (HRQoL) in rheumatoid arthritis] |
| Q84600236 | [How do we evaluate an inadequate response in a patient with rheumaoid arthritis in the clinical praxis P?] |
| Q80809043 | [International classification of functioning, disability and health and its significance for rheumatology] |
| Q84600661 | [Is the DAS28 Score the Most Adequate Method to Estimate Activity in Rheumatoid Arthritis? Clinimetric Considerations and Simulations Scenarios] |
| Q52941949 | [Out-of-pocket medical spending for care in patients with recent onset rheumatoid arthritis]. |
| Q82663598 | [Outcome parameters for use in psoriatic arthritis] |
| Q52933137 | [Pregnancy in patients with rheumatoid arthritis and inflammatory spondylarthropathies]. |
| Q79691497 | [Rheumatological rehabilitation today. Exemplified by two case reports] |
| Q74042917 | [Systematic review of clinical trials on the treatment of rheumatoid arthritis with tumour necrosis factor alpha inhibitors] |
| Q53626772 | [The influence of physical function on the risk of falls among adults with rheumatoid arthritis]. |
| Q57056387 | [What is certain in the treatment of rheumatoid arthritis?] |
| Q38751251 | bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search |
| Q48171338 | mRNA profilin identifies low levels of phosphatases dual-specific phosphatase-7 (DUSP7) and cell division cycle-25B (CDC25B) in patients with early arthritis. |
| Q43057563 | β1,4-Galactosyltransferase-I contributes to the inflammatory processes in synovial tissue of patients with rheumatoid arthritis |